Submitted URL: http://link.email.empr.com/a/1323/click/68826/2303653/81342646d2149b6565202cdceb90aa05dc1079de/6fe7119f58b2152a2ec9475bf11c...
Effective URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-dat...
Submission: On September 27 via api from US

Summary

This website contacted 44 IPs in 7 countries across 36 domains to perform 228 HTTP transactions. The main IP is 52.0.128.45, located in Ashburn, United States and belongs to AMAZON-AES - Amazon.com, Inc., US. The main domain is www.empr.com.
TLS certificate: Issued by RapidSSL RSA CA 2018 on January 16th 2019. Valid for: 2 years.
This is the only time www.empr.com was scanned on urlscan.io!

urlscan.io Verdict: No classification

Domain & IP information

IP Address AS Autonomous System
1 2 35.238.92.4 15169 (GOOGLE)
34 52.0.128.45 14618 (AMAZON-AES)
24 94.31.29.64 33438 (HIGHWINDS2)
3 2a00:1450:400... 15169 (GOOGLE)
1 93.184.220.113 15133 (EDGECAST)
6 2a00:1450:400... 15169 (GOOGLE)
4 52.216.171.93 16509 (AMAZON-02)
1 2a00:1450:400... 15169 (GOOGLE)
1 2600:9000:20b... 16509 (AMAZON-02)
9 172.217.16.162 15169 (GOOGLE)
1 2606:4700::68... 13335 (CLOUDFLAR...)
1 6 2a00:1450:400... 15169 (GOOGLE)
1 4 2.19.43.224 20940 (AKAMAI-ASN1)
4 2a00:1450:400... 15169 (GOOGLE)
1 143.204.214.38 16509 (AMAZON-02)
3 2a03:2880:f01... 32934 (FACEBOOK)
2 2 54.156.255.160 14618 (AMAZON-AES)
2 2 35.227.248.159 15169 (GOOGLE)
1 34.225.65.223 14618 (AMAZON-AES)
1 143.204.207.113 16509 (AMAZON-02)
67 2606:4700:20:... 13335 (CLOUDFLAR...)
1 34.192.84.248 14618 (AMAZON-AES)
1 143.204.214.3 16509 (AMAZON-02)
4 52.3.171.116 14618 (AMAZON-AES)
2 8 34.252.62.73 16509 (AMAZON-02)
1 1 2a00:1450:400... 15169 (GOOGLE)
1 1 2a00:1450:400... 15169 (GOOGLE)
1 2a00:1450:400... 15169 (GOOGLE)
3 2a03:2880:f11... 32934 (FACEBOOK)
1 35.175.13.58 14618 (AMAZON-AES)
1 1 104.111.241.32 16625 (AKAMAI-AS)
2 2 35.190.72.21 15169 (GOOGLE)
2 2 2.18.233.201 16625 (AKAMAI-AS)
2 3 34.250.208.218 16509 (AMAZON-02)
2 3 18.197.149.199 16509 (AMAZON-02)
2 35.227.192.113 15169 (GOOGLE)
4 3.209.234.104 14618 (AMAZON-AES)
6 2a00:1450:400... 15169 (GOOGLE)
4 34.197.62.58 14618 (AMAZON-AES)
1 143.204.214.23 16509 (AMAZON-02)
1 34.225.50.222 14618 (AMAZON-AES)
4 2600:9000:20b... 16509 (AMAZON-02)
2 143.204.214.75 16509 (AMAZON-02)
3 2600:1f14:e96... 16509 (AMAZON-02)
1 3 2600:1f14:e96... 16509 (AMAZON-02)
2 6 2600:1f14:e96... 16509 (AMAZON-02)
1 54.245.184.141 16509 (AMAZON-02)
2 34.219.221.191 16509 (AMAZON-02)
2 2a00:1450:400... 15169 (GOOGLE)
1 52.51.120.75 16509 (AMAZON-02)
228 44
Apex Domain
Subdomains
Transfer
69 lytics.io
c.lytics.io
api.lytics.io
87 KB
34 empr.com
link.email.empr.com
www.empr.com
media.empr.com
3 MB
24 netdna-ssl.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
253 KB
15 b2c.com
api.b2c.com
api-54-245-184-141.b2c.com
api-34-219-221-191.b2c.com
20 KB
10 doubleclick.net
securepubads.g.doubleclick.net
stats.g.doubleclick.net
100 KB
9 ml314.com
ml314.com
in.ml314.com
17 KB
9 haymarketmedia.com
accounts.haymarketmedia.com
subapi.haymarketmedia.com
adtrackapi.haymarketmedia.com
12 KB
8 googlesyndication.com
tpc.googlesyndication.com
pagead2.googlesyndication.com
156 KB
6 spotible.com
ads.spotible.com
cdn1.spotible.com
217 KB
6 google-analytics.com
www.google-analytics.com
40 KB
4 medtargetsystem.com
www.medtargetsystem.com
53 KB
4 gstatic.com
fonts.gstatic.com
50 KB
4 scorecardresearch.com
sb.scorecardresearch.com
3 KB
4 amazonaws.com
s3.amazonaws.com
2 MB
4 googletagservices.com
www.googletagservices.com
101 KB
4 crwdcntrl.net
tags.crwdcntrl.net
sync.crwdcntrl.net
bcp.crwdcntrl.net
13 KB
3 eyeota.net
ps.eyeota.net
1 KB
3 facebook.com
www.facebook.com
247 B
3 sitomobile.com
mt.sitomobile.com
sp.sitomobile.com
2 KB
3 facebook.net
connect.facebook.net
119 KB
3 googleapis.com
fonts.googleapis.com
2 KB
2 mathtag.com
pixel.mathtag.com
1 KB
2 rlcdn.com
idsync.rlcdn.com
845 B
2 adsrvr.org
js.adsrvr.org
insight.adsrvr.org
2 KB
2 tapad.com
pixel.tapad.com
844 B
2 google.com
adservice.google.com
www.google.com
361 B
2 google.de
adservice.google.de
www.google.de
280 B
2 maropost.com
content.maropost.com
mpct1.maropost.com
5 KB
1 hematologyadvisor.com
www.hematologyadvisor.com
35 KB
1 rheumatologyadvisor.com
www.rheumatologyadvisor.com
66 KB
1 thecardiologyadvisor.com
www.thecardiologyadvisor.com
488 KB
1 bluekai.com
tags.bluekai.com
858 B
1 alexametrics.com
certify.alexametrics.com
552 B
1 cloudfront.net
d31qbv1cthcecs.cloudfront.net
2 KB
1 crazyegg.com
script.crazyegg.com
28 KB
1 googletagmanager.com
www.googletagmanager.com
34 KB
228 36
Domain Requested by
67 c.lytics.io 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
c.lytics.io
www.empr.com
32 www.empr.com www.empr.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
24 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com www.empr.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
9 securepubads.g.doubleclick.net www.googletagservices.com
securepubads.g.doubleclick.net
www.empr.com
8 api-34-219-221-191.b2c.com 2 redirects www.empr.com
8 ml314.com 2 redirects www.empr.com
ml314.com
6 tpc.googlesyndication.com securepubads.g.doubleclick.net
6 www.google-analytics.com 1 redirects www.googletagmanager.com
www.google-analytics.com
4 api-54-245-184-141.b2c.com 1 redirects www.empr.com
4 adtrackapi.haymarketmedia.com s3.amazonaws.com
4 ads.spotible.com www.empr.com
ads.spotible.com
4 subapi.haymarketmedia.com s3.amazonaws.com
4 www.medtargetsystem.com www.empr.com
www.medtargetsystem.com
4 fonts.gstatic.com www.empr.com
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
4 sb.scorecardresearch.com 1 redirects www.empr.com
www.googletagmanager.com
4 s3.amazonaws.com www.empr.com
4 www.googletagservices.com www.empr.com
securepubads.g.doubleclick.net
3 api.b2c.com securepubads.g.doubleclick.net
www.empr.com
3 ps.eyeota.net 2 redirects www.empr.com
3 www.facebook.com www.empr.com
connect.facebook.net
3 connect.facebook.net www.empr.com
connect.facebook.net
3 fonts.googleapis.com www.empr.com
s3.amazonaws.com
2 pagead2.googlesyndication.com www.empr.com
2 cdn1.spotible.com www.empr.com
2 api.lytics.io c.lytics.io
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
2 sync.crwdcntrl.net 2 redirects
2 pixel.mathtag.com 2 redirects
2 idsync.rlcdn.com 2 redirects
2 pixel.tapad.com 2 redirects
2 mt.sitomobile.com 2 redirects
1 insight.adsrvr.org js.adsrvr.org
1 bcp.crwdcntrl.net tags.crwdcntrl.net
1 www.hematologyadvisor.com www.empr.com
1 www.rheumatologyadvisor.com www.empr.com
1 media.empr.com www.empr.com
1 www.thecardiologyadvisor.com www.empr.com
1 tags.bluekai.com 1 redirects
1 in.ml314.com ml314.com
1 www.google.de www.empr.com
1 www.google.com 1 redirects
1 stats.g.doubleclick.net 1 redirects
1 certify.alexametrics.com www.empr.com
1 accounts.haymarketmedia.com 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
1 mpct1.maropost.com content.maropost.com
1 js.adsrvr.org www.googletagmanager.com
1 sp.sitomobile.com www.empr.com
1 d31qbv1cthcecs.cloudfront.net www.empr.com
1 script.crazyegg.com www.googletagmanager.com
1 adservice.google.com www.googletagservices.com
1 adservice.google.de www.googletagservices.com
1 content.maropost.com www.empr.com
1 www.googletagmanager.com www.empr.com
1 tags.crwdcntrl.net www.empr.com
1 link.email.empr.com 1 redirects
228 54
Subject Issuer Validity Valid
*.empr.com
RapidSSL RSA CA 2018
2019-01-16 -
2021-01-15
2 years crt.sh
*.netdna-ssl.com
Sectigo RSA Domain Validation Secure Server CA
2019-02-18 -
2020-02-27
a year crt.sh
*.googleapis.com
GTS CA 1O1
2019-09-05 -
2019-11-28
3 months crt.sh
tags.crwdcntrl.net
DigiCert SHA2 Secure Server CA
2019-03-15 -
2021-04-07
2 years crt.sh
*.g.doubleclick.net
GTS CA 1O1
2019-09-05 -
2019-11-28
3 months crt.sh
s3.amazonaws.com
DigiCert Baltimore CA-2 G2
2019-09-06 -
2020-12-02
a year crt.sh
*.google-analytics.com
GTS CA 1O1
2019-09-05 -
2019-11-28
3 months crt.sh
content.maropost.com
Amazon
2018-10-25 -
2019-11-25
a year crt.sh
*.google.com
GTS CA 1O1
2019-09-05 -
2019-11-28
3 months crt.sh
ssl945600.cloudflaressl.com
COMODO ECC Domain Validation Secure Server CA 2
2019-08-20 -
2020-02-26
6 months crt.sh
*.scorecardresearch.com
COMODO RSA Organization Validation Secure Server CA
2018-11-28 -
2019-12-26
a year crt.sh
*.cloudfront.net
DigiCert Global CA G2
2019-07-17 -
2020-07-05
a year crt.sh
*.facebook.com
DigiCert SHA2 High Assurance Server CA
2019-08-24 -
2019-10-19
2 months crt.sh
*.sitomobile.com
RapidSSL RSA CA 2018
2018-01-22 -
2020-07-29
3 years crt.sh
*.adsrvr.org
Trustwave Organization Validation SHA256 CA, Level 1
2019-03-07 -
2021-04-19
2 years crt.sh
*.maropost.com
Go Daddy Secure Certificate Authority - G2
2019-06-10 -
2021-08-09
2 years crt.sh
ssl379818.cloudflaressl.com
COMODO ECC Domain Validation Secure Server CA 2
2019-07-26 -
2020-02-01
6 months crt.sh
accounts.haymarketmedia.com
Amazon
2018-10-26 -
2019-11-26
a year crt.sh
certify.alexametrics.com
Amazon
2019-07-26 -
2020-08-26
a year crt.sh
medtargetsystem.com
Amazon
2018-11-23 -
2019-12-23
a year crt.sh
*.ml314.com
Amazon
2019-03-16 -
2020-04-16
a year crt.sh
www.google.de
GTS CA 1O1
2019-09-05 -
2019-11-28
3 months crt.sh
*.eyeota.net
Let's Encrypt Authority X3
2019-09-19 -
2019-12-18
3 months crt.sh
*.lytics.io
RapidSSL TLS RSA CA G1
2018-01-26 -
2020-01-06
2 years crt.sh
subapi.haymarketmedia.com
Amazon
2019-06-28 -
2020-07-28
a year crt.sh
tpc.googlesyndication.com
GTS CA 1O1
2019-09-05 -
2019-11-28
3 months crt.sh
*.spotible.com
Go Daddy Secure Certificate Authority - G2
2016-10-16 -
2019-11-06
3 years crt.sh
*.thecardiologyadvisor.com
RapidSSL RSA CA 2018
2019-02-20 -
2020-02-20
a year crt.sh
empr.com
Amazon
2018-11-08 -
2019-12-08
a year crt.sh
*.rheumatologyadvisor.com
RapidSSL RSA CA 2018
2019-02-20 -
2020-02-20
a year crt.sh
*.hematologyadvisor.com
RapidSSL RSA CA 2018
2019-02-07 -
2020-02-07
a year crt.sh
adtrackapi.haymarketmedia.com
Amazon
2019-03-27 -
2020-04-27
a year crt.sh
*.b2c.com
Amazon
2019-03-24 -
2020-04-24
a year crt.sh
*.crwdcntrl.net
Go Daddy Secure Certificate Authority - G2
2019-06-13 -
2021-06-28
2 years crt.sh

This page contains 11 frames:

Primary Page: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Frame ID: FB99A3D5C73ACCD5018EE088A93CA389
Requests: 206 HTTP requests in this frame

Frame: https://api.lytics.io/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/d687c1b7707b466c930381252610bbb5?segments=true&mergestate=true&ts=1569558862561
Frame ID: 531F3D90AD60AFFD9CBB61C214CE450B
Requests: 1 HTTP requests in this frame

Frame: https://www.medtargetsystem.com/beacon/portal/?_url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F&_sid=f547e0be-0ebd-4871-b467-fcedb6a3378c&_vid=7c974a5a-0603-4536-ab27-3a3c6c561821&_ak=35-212-8F62AC13&_flash=false&_th=1569558862|1569558862|1
Frame ID: 5CFDF9AF9EA9DC8D271F82FF43DCDB52
Requests: 1 HTTP requests in this frame

Frame: https://www.facebook.com/tr/
Frame ID: DDFF4FAF007B616CEAFA09CE198D757E
Requests: 1 HTTP requests in this frame

Frame: https://www.facebook.com/tr/
Frame ID: 9E83506EF64D686A546706F1B8DA4AB3
Requests: 1 HTTP requests in this frame

Frame: https://ads.spotible.com/tag/universal-tag.js
Frame ID: F961DD0382454134AA15A593067D88FD
Requests: 2 HTTP requests in this frame

Frame: https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsvukIJgpY6I_9m6us_-K8l9mJOz7_fXIaVeDk5IdOeiQS_B8eY0GeBxsbD-eZgj3ZURUqLCl6VlIK5oef-TCXdYYK9_dHE6EWYmQDPaxamfbBWkaPvyhaHcqfvVoSt3NAeM5IGZEiVDGYyUUxUQulv_htoWcM_v2TiijbusREXaAGuUuw0bk6s5gEJYFotPUtQZuTXKGHQSYt7lPtEj6dOXbq3oh_Dr6Z4FxnPWrUzQUEqFS54Xa5jvczC9UnTQRmQXNDyI79FNw7Z5di-wJ27P_Q&sig=Cg0ArKJSzMYxunNUjQVCEAE&adurl=
Frame ID: 000DFD7F3AB8DDF5F2C5DAD8746A099F
Requests: 10 HTTP requests in this frame

Frame: https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsvXuVm1aFMtr7MpavQRBrKbobmGi6HXrKPDVSKICaXzUBC0s6td129gVT99ikNMiIdX6A6cHELBT4yoSZUv_SDKR-vpytKfzkvt-vTnBC2gM_ysrOYCzxZdfgC5NTfZJPrwdz1hHpQmvJcJOyf95eBs9hOkueldC7QZp6h0G60cKanu-oYkulciAxn34A5MTF8IN38-6SyYK-hQGyyuTCUDfUoMNuV_l50aXefOfbujlCyw2tk-fi-Gsc4LkIBO5Js4gRnDpzXN&sig=Cg0ArKJSzP7aNCin1vhREAE&adurl=
Frame ID: 5AC9C21D67FF28A3DEF5C2D5A907A907
Requests: 10 HTTP requests in this frame

Frame: https://tpc.googlesyndication.com/safeframe/1-0-35/html/container.html
Frame ID: DEDF07102840D66E886AB05B5AC5D0EC
Requests: 1 HTTP requests in this frame

Frame: https://bcp.crwdcntrl.net/5/c=14413/rand=608981664/pv=y/ver=1.4/int=%23OpR%2396858%23Total%20Site%20Traffic%20%3A%20www.empr.com/int=%23OpR%2396859%23www.empr.com%20%3A%20Site%20Section%20%3A%20home/int=%23OpR%2396860%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%20%3A%20news/int=%23OpR%2397492%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%3A%20news%20%3A%20first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/med=%23OpR%2397539%23Article%20Tags%20%3A%20Oncology%2CRespiratory%20and%20Thoracic%20Cancers/rb=%7B%22url%22%3A%22https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653%22%7D/rt=ifr
Frame ID: 2B7F0B63EAB179A9C162D568270869B3
Requests: 1 HTTP requests in this frame

Frame: https://insight.adsrvr.org/track/up?adv=wxli9bh&ref=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&upid=7fhq4wn&upv=1.1.0
Frame ID: 859EDC2315A175E553B930BD8FA12C35
Requests: 1 HTTP requests in this frame

Screenshot


Page URL History Show full URLs

  1. http://link.email.empr.com/a/1323/click/68826/2303653/81342646d2149b6565202cdceb90aa05dc1079de/6fe7119f... HTTP 302
    https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-... Page URL

Detected technologies

Overall confidence: 100%
Detected patterns
  • headers link /rel="https:\/\/api\.w\.org\/"/i

Overall confidence: 100%
Detected patterns
  • headers link /rel="https:\/\/api\.w\.org\/"/i

Overall confidence: 100%
Detected patterns
  • headers link /rel="https:\/\/api\.w\.org\/"/i

Overall confidence: 100%
Detected patterns
  • headers server /nginx(?:\/([\d.]+))?/i

Overall confidence: 100%
Detected patterns
  • script /script\.crazyegg\.com\/pages\/scripts\/\d+\/\d+\.js/i

Overall confidence: 100%
Detected patterns
  • script /\/\/connect\.facebook\.net\/[^\/]*\/[a-z]*\.js/i

Overall confidence: 100%
Detected patterns
  • script /google-analytics\.com\/(?:ga|urchin|analytics)\.js/i

Overall confidence: 100%
Detected patterns
  • html /googletagmanager\.com\/ns\.html[^>]+><\/iframe>/i
  • html /<!-- (?:End )?Google Tag Manager -->/i

Page Statistics

228
Requests

100 %
HTTPS

38 %
IPv6

36
Domains

54
Subdomains

44
IPs

7
Countries

6578 kB
Transfer

8879 kB
Size

47
Cookies

Page URL History

This captures the URL locations of the websites, including HTTP redirects and client-side redirects via JavaScript or Meta fields.

  1. http://link.email.empr.com/a/1323/click/68826/2303653/81342646d2149b6565202cdceb90aa05dc1079de/6fe7119f58b2152a2ec9475bf11c05168b614aa0&amp HTTP 302
    https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653 Page URL

Redirected requests

There were HTTP redirect chains for the following requests:

Request Chain 39
  • https://sb.scorecardresearch.com/b?c1=2&c2=21948019&ns__t=1569558861891&ns_c=UTF-8&c8=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&c9= HTTP 302
  • https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1569558861891&ns_c=UTF-8&c8=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&c9=
Request Chain 50
  • https://mt.sitomobile.com/sync/ta?aid=136&sid=hmm&val=12 HTTP 302
  • https://pixel.tapad.com/idsync/ex/push?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12 HTTP 302
  • https://pixel.tapad.com/idsync/ex/push/check?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12 HTTP 302
  • https://mt.sitomobile.com/sync/tacb?exid=141afd41-e0e0-11e9-8dcb-52c7686934ad&aid=136&sid=hmm&val=12 HTTP 302
  • https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L2Nvb2tpZV9zeW5jL2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InBhcnRuZXJJZCI6InRhcGFkIn19fQ%3D%3D&cx=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
Request Chain 65
  • https://www.google-analytics.com/r/collect?v=1&_v=j79&a=652718221&t=pageview&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&ul=en-us&de=UTF-8&dt=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&sd=24-bit&sr=1600x1200&vp=1585x1200&je=0&_u=aGDAAAAjQ~&jid=2034178867&gjid=1546333091&cid=408063271.1569558862&tid=UA-1290429-2&_gid=2019810217.1569558862&_r=1&gtm=2wg9i15XFK9V6&cd1=124026%3A0&cd2=oncology%2Crespiratory%20and%20thoracic%20cancers&cd3=&cd4=&cd5=post&cd6=&cd7=home&cd8=news&cd9=first-line%20pembrolizumab%20effective%20in%20advanced%20nsclc%2C%20according%20to%203-year%20follow-up%20data&cd11=omn&cd12=13&cd14=false&cd15=&cd16=false&cd17=&cd18=0&cd19=&cd31=&cd32=&cd33=&cd34=Brian%20Park%2C%20PharmD&cd35=MPR%20Drug%20News&cd36=&cd37=undefined&cd38=undefined&cd39=undefined&cd40=&cd41=&cd42=&cd43=&cd46=&cd48=&cd50=&cd52=&cd53=home&cd54=&cd55=&cd56=9&cd57=&cd58=&cd62=false&cd63=2019-09-17&cd64=338&cd67=&cd68=undef&cd71=false&cd78=false&cd79=false&cd80=false&cd93=news&cd94=placeholder&z=68886949 HTTP 302
  • https://stats.g.doubleclick.net/r/collect?v=1&aip=1&t=dc&_r=3&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_gid=2019810217.1569558862&gjid=1546333091&_v=j79&z=68886949 HTTP 302
  • https://www.google.com/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_v=j79&z=68886949 HTTP 302
  • https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_v=j79&z=68886949&slf_rd=1&random=2208599624
Request Chain 70
  • https://tags.bluekai.com/site/20486?limit=0&id=5978151501699112544&redir=https://ml314.com/csync.ashx%3Ffp=$_BK_UUID%26person_id=5978151501699112544%26eid=50056 HTTP 302
  • https://ml314.com/csync.ashx?fp=278Fwy9999O%2FyRN5&person_id=5978151501699112544&eid=50056
Request Chain 71
  • https://idsync.rlcdn.com/395886.gif?partner_uid=5978151501699112544 HTTP 307
  • https://idsync.rlcdn.com/1000.gif?memo=CO6UGBIeChoIARCuXxoTNTk3ODE1MTUwMTY5OTExMjU0NBAAGg0IzqK27AUSBQjoBxAAQgBKAA HTTP 307
  • https://ml314.com/csync.ashx?fp=6e67f63b765426c642c90950500af282bfac8db5932c08ae4752ff2b5eab7287f4cb09cee1a4f8eb&person_id=5978151501699112544&eid=50082
Request Chain 72
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151501699112544%26eid=50220 HTTP 302
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151501699112544%26eid=50220&mm_bnc&mm_bct&UUID=1bc15d8d-89f2-4d00-b9a6-c1aaea5e249a HTTP 302
  • https://ml314.com/csync.ashx?fp=1bc15d8d-89f2-4d00-b9a6-c1aaea5e249a&person_id=5978151501699112544&eid=50220
Request Chain 73
  • https://sync.crwdcntrl.net/map/c=6985/tp=BOMB?https://ml314.com/csync.ashx%3Ffp%3D%24%7Bprofile_id%7D%26eid%3D50146%26person_id%3D5978151501699112544 HTTP 302
  • https://sync.crwdcntrl.net/map/ct=y/c=6985/tp=BOMB?https://ml314.com/csync.ashx%3Ffp%3D%24%7Bprofile_id%7D%26eid%3D50146%26person_id%3D5978151501699112544 HTTP 302
  • https://ml314.com/csync.ashx?fp=f7dd9557544444e75f3969dd39dba5bc&eid=50146&person_id=5978151501699112544
Request Chain 74
  • https://ps.eyeota.net/pixel?pid=r8hrb20&t=gif HTTP 302
  • https://ps.eyeota.net/pixel/bounce/?pid=r8hrb20&t=gif HTTP 302
  • https://ml314.com/utsync.ashx?eid=50052&et=0&fp=2QOmpmvYJ5L28GWDWQDVK7DrQuMM7KAztUtlnnCCZmlM&gdpr=1&gdpr_consent=&return=https%3A%2F%2Fps.eyeota.net%2Fmatch%3Fbid%3Dr8hrb20%26uid%3Dnil HTTP 302
  • https://ml314.com/csync.ashx?fp=2QOmpmvYJ5L28GWDWQDVK7DrQuMM7KAztUtlnnCCZmlM&person_id=5978151501699112544&eid=50052&return=https%3a%2f%2fps.eyeota.net%2fmatch%3fbid%3dr8hrb20%26uid%3dnil HTTP 302
  • https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
Request Chain 217
  • https://api-54-245-184-141.b2c.com/api/x?hIO8Wz07ydJEoMhN$dXJsJDAkaHR0cHM6Ly93d3cuZW1wci5jb20vaG9tZS9uZXdzL2ZpcnN0LWxpbmUtcGVtYnJvbGl6dW1hYi1lZmZlY3RpdmUtaW4tYWR2YW5jZWQtbnNjbGMtYWNjb3JkaW5nLXRvLTMteWVhci1mb2xsb3ctdXAtZGF0YS8_dXRtX3NvdXJjZT1uZXdzbGV0dGVyJnV0bV9tZWRpdW09ZW1haWwmdXRtX2NhbXBhaWduPW1wci1zcG90bGlnaHQtaGF5LTIwMTkwOTI3JmNwbj1wY3BfbWQsZnBfbWQscGNwX2FsbCxoYXJ2b25pdGJnLGVwY2x1c2FsaXN0Yl9qYW4yMDE5LGVwY2x1c2FfYXByaWxfMjAxOSZobVN1YklkPSZobUVtYWlsPTh0ODVPYU1uQXRkc2VZbDFLc0hWV3BlVnAxdzE0OHRiUGNNekF1VWNrNUUxJk5JRD0xNjE5OTA5OTc1JmNfaWQ9JmVtYWlsX2hhc2g9MTNmY2Y4MGI4MDk3ZWVkMTg2ZTA3ZGIxOWZkM2MyYzYmZGw9MCZtcHdlYj0xMzIzLTY4ODI2LTIzMDM2NTMiLCJyZWZlcnJlciQwJCIsImFuY2VzdG9yT3JpZ2lucyQwJGh0dHBzOi8vd3d3LmVtcHIuY29tIiwidmlkZW8kMCQxNjAweDEyMDB4MjQiLCJmcmFtZSQwJDEiLCJoaWRkZW4kMCQwIiwidmlzaWJpbGl0eVN0YXRlJDAkdmlzaWJsZSIsImhhc0ZvY3VzJDAkMCIsIndpbmRvdyQwJDMwMHg2MDAiLCJpbm5lciQwJDMwMHg2MDAiLCJvdXRlciQwJDE2MDB4MTIwMCIsImxvY2FsU3RvcmFnZSQwJEVycm9yOiBUeXBlRXJyb3I6IENhbm5vdCByZWFkIHByb3BlcnR5ICdzZXRJdGVtJyBvZiBudWxsIiwic2Vzc2lvblN0b3JhZ2UkMCQxIiwiYXBwQ29kZU5hbWUkMCRNb3ppbGxhIiwiYXBwTmFtZSQwJE5ldHNjYXBlIiwiYXBwVmVyc2lvbiQwJDUuMCAoTWFjaW50b3NoOyBJbnRlbCBNYWMgT1MgWCAxMF8xNF81KSBBcHBsZVdlYktpdC81MzcuMzYgKEtIVE1MLCBsaWtlIEdlY2tvKSBDaHJvbWUvNzQuMC4zNzI5LjE2OSBTYWZhcmkvNTM3LjM2IiwiY29va2llRW5hYmxlZCQwJHRydWUiLCJkb05vdFRyYWNrJDAkIiwiaGFyZHdhcmVDb25jdXJyZW5jeSQwJDE2IiwibGFuZ3VhZ2UkMCRlbi1VUyIsInBsYXRmb3JtJDAkTGludXggeDg2XzY0IiwicHJvZHVjdCQwJEdlY2tvIiwicHJvZHVjdFN1YiQwJDIwMDMwMTA3Iiwic2VuZEJlYWNvbiQwJDEiLCJ1c2VyQWdlbnQkMSRNb3ppbGxhLzUuMCAoTWFjaW50b3NoOyBJbnRlbCBNYWMgT1MgWCAxMF8xNF81KSBBcHBsZVdlYktpdC81MzcuMzYgKEtIVE1MLCBsaWtlIEdlY2tvKSBDaHJvbWUvNzQuMC4zNzI5LjE2OSBTYWZhcmkvNTM3LjM2IiwidmVuZG9yJDEkR29vZ2xlIEluYy4iLCJ2ZW5kb3JTdWIkMSQiLCJmb250cmVuZGVyJDQkMSIsIndlYmdsJDUkbi9hIiwid2ViZ2wyJDUkMCIsInRpbWUkNSQxNTY5NTU4ODY0OTk0IiwidGltZXpvbmUkNSQtMTIwIiwicGx1Z2lucyQ1JE5vbmUiLCJtZW0tdG90YWxKU0hlYXBTaXplJDYkMzkuODA3MDE0IiwibWVtLXVzZWRKU0hlYXBTaXplJDYkMzIuNDg4NDM4IiwibWVtLWpzSGVhcFNpemVMaW1pdCQ2JDQzNDUuMjk4OTQ0IiwidGltZS1yZXNwb25zZUVuZCQ2JDEiLCJ0aW1lLWRvbUxvYWRpbmckNiQxIiwidGltZS1kb21JbnRlcmFjdGl2ZSQ2JDEiLCJ0aW1lLWRvbUNvbnRlbnRMb2FkZWRFdmVudFN0YXJ0JDYkMSIsInRpbWUtZG9tQ29udGVudExvYWRlZEV2ZW50RW5kJDYkMSIsInRpbWUtZG9tQ29tcGxldGUkNiQxIiwibmF2aWdhdGlvbi1yZWRpcmVjdENvdW50JDYkMCIsIm5hdmlnYXRpb24tdHlwZSQ2JG5hdmlnYXRlIiwiZ2xvYmFscy10aW1lJDEwJDAuNTM1IiwiZ2xvYmFscyQxMCQxYmY5YTlmYiIsImRvY3VtZW50LXRpbWUkMTMkMC43MTUiLCJkb2N1bWVudCQxMyQ4YmI3MWFkMiIsImNvbm5lY3Rpb24kMTMkIiwiZG93bmxpbmtNYXgkMTMkIiwiZ2V0VXNlck1lZGlhJDEzJDIiLCJjbG9jayQxNyQ0NzcxIiwiYmF0dGVyeSQyMCQxIDEgMCBJbmZpbml0eSIsImludGVyc2VjdGlvbi1zaXplJDIwJDE1ODV4MTIwMCIsImludGVyc2VjdGlvbi1lbnRlciQyMCQwLjV4MCAzMDB4MCIsImludGVyc2VjdGlvbiQyMCQxMDAiLCJhdWRpb2NvbnRleHQkMjEkZGM2NmE2MjgiLCJzb3J0JDU4JDE3LjE5IiwiZnJhbWVyYXRlJDEyMyQ5MA HTTP 302
  • https://api-54-245-184-141.b2c.com:444/api/4?hIO8Wz07ydJEoMhN
Request Chain 218
  • https://api-34-219-221-191.b2c.com/api/x?SjFZ9AIdsawFR0hY$dXJsJDAkaHR0cHM6Ly93d3cuZW1wci5jb20vaG9tZS9uZXdzL2ZpcnN0LWxpbmUtcGVtYnJvbGl6dW1hYi1lZmZlY3RpdmUtaW4tYWR2YW5jZWQtbnNjbGMtYWNjb3JkaW5nLXRvLTMteWVhci1mb2xsb3ctdXAtZGF0YS8_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 HTTP 302
  • https://api-34-219-221-191.b2c.com:444/api/4?SjFZ9AIdsawFR0hY
Request Chain 230
  • https://api-34-219-221-191.b2c.com/api/x?tKqdPazai1XIUSUC$dXJsJDAkaHR0cHM6Ly93d3cuZW1wci5jb20vaG9tZS9uZXdzL2ZpcnN0LWxpbmUtcGVtYnJvbGl6dW1hYi1lZmZlY3RpdmUtaW4tYWR2YW5jZWQtbnNjbGMtYWNjb3JkaW5nLXRvLTMteWVhci1mb2xsb3ctdXAtZGF0YS8_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 HTTP 302
  • https://api-34-219-221-191.b2c.com:444/api/4?tKqdPazai1XIUSUC

228 HTTP transactions

Resource
Path
Size
x-fer
Type
MIME-Type
Primary Request /
www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/
Redirect Chain
  • http://link.email.empr.com/a/1323/click/68826/2303653/81342646d2149b6565202cdceb90aa05dc1079de/6fe7119f58b2152a2ec9475bf11c05168b614aa0&amp
  • https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-2019092...
103 KB
23 KB
Document
General
Full URL
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
cf0bd86e5804225658fbc1dbc0191853224c5779e933b8e9e4c407da7101edfc

Request headers

:method
GET
:authority
www.empr.com
:scheme
https
:path
/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
none
accept-encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

status
200
server
nginx
date
Fri, 27 Sep 2019 04:34:21 GMT
content-type
text/html; charset=UTF-8
vary
Accept-Encoding Accept-Encoding Accept-Encoding,Cookie,X-WPENGINE-SEGMENT
x-distributor
yes
x-pingback
https://www.empr.com/xmlrpc.php
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/" <https://www.empr.com/?p=124026>; rel=shortlink
x-cacheable
SHORT
cache-control
max-age=600, must-revalidate
x-cache
MISS
x-pass-why
x-cache-group
normal
x-wpengine-segment
NONHT
content-encoding
gzip

Redirect headers

Content-Type
text/html; charset=utf-8
Transfer-Encoding
chunked
Connection
keep-alive
Status
302 Found
Cache-Control
no-cache
X-XSS-Protection
1; mode=block
X-Request-Id
eea2493b-d27c-41e3-bbd4-5c1433e6d034
Location
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
X-Runtime
0.026246
X-Frame-Options
SAMEORIGIN
X-Content-Type-Options
nosniff
Date
Fri, 27 Sep 2019 04:34:20 GMT
Set-Cookie
_session_id=eb4bf630f6fe95c6a45d73dd23e7cec9; path=/; expires=Fri, 27 Sep 2019 16:34:20 -0000; HttpOnly
X-Powered-By
Phusion Passenger 5.3.4
Server
nginx/1.14.0 + Phusion Passenger 5.3.4
style.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/css/dist/block-library/
29 KB
5 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/css/dist/block-library/style.min.css?ver=5.2.3
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
4b8fe5c3d0e5ef7a6582185cbf5c535b5d369c8df1da98c03ed69833e55f474d

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Mon, 22 Apr 2019 12:40:04 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5cbdb624-726f"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=31536000
shared-style.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/
48 KB
7 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/shared-style.min.css?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
33fe4fe8214760f15a5fdd753b5c396ee5b916e5d6f66f79d4765ed260706723

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-c05a"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=31536000
style.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/
240 KB
32 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/style.min.css?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
f1e3884dae2f0ddd32795c0c1ac83e9f9a8c7dce35dbd784bdc3c9872196bb1c

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-3bfb4"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=31536000
css
fonts.googleapis.com/
8 KB
814 B
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:806::200a Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
ESF /
Resource Hash
bb4c48e63332f312f4d1945747e9e319247d26592eec54e38fe75eff833eb130
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000
content-encoding
br
last-modified
Fri, 27 Sep 2019 04:34:21 GMT
server
ESF
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
status
200
date
Fri, 27 Sep 2019 04:34:21 GMT
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:21 GMT
lytics.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/
39 KB
3 KB
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/lytics.min.css?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
6944e75951f2e7bf00121eea502e7d952a833e811e13a1f28fb077df6af721f3

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-9de9"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=31536000
css
fonts.googleapis.com/
825 B
455 B
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Bree+Serif&ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:806::200a Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
ESF /
Resource Hash
19aa6c614f72f6bb67cb17a6169ca551686c2bab5475293c95880f5f32cd830e
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000
content-encoding
br
last-modified
Fri, 27 Sep 2019 04:34:21 GMT
server
ESF
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
status
200
date
Fri, 27 Sep 2019 04:34:21 GMT
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:21 GMT
autosuggest.min.css
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/css/
766 B
581 B
Stylesheet
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/css/autosuggest.min.css?ver=3.1.4
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
8689484e31c0c85e3e074f0b59348974f5de4b2eec412e388e2ea32924a41478

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Wed, 10 Jul 2019 08:59:26 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d25a8ee-2fe"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
text/css
access-control-allow-origin
*
cache-control
public, max-age=31536000
jquery.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/
95 KB
34 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery.js?ver=1.12.4-wp
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
1db21d816296e6939ba1f42962496e4134ae2b0081e26970864c40c6d02bb1df

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Fri, 17 May 2019 17:08:53 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5cdeeaa5-17a69"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
jquery-migrate.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/
10 KB
4 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=1.4.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
48eb8b500ae6a38617b5738d2b3faec481922a7782246e31d2755c034a45cd5d

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Fri, 20 May 2016 06:11:28 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"573eaa90-2748"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
cookie.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/mu-plugins/cookie-controller/js/
2 KB
1 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/mu-plugins/cookie-controller/js/cookie.min.js?ver=1.2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
e828282e92509efc0f7bc57888382c5816bd403e0abbb685eda5c4372cc7daa5

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-834"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
cc.js
tags.crwdcntrl.net/c/14413/
39 KB
11 KB
Script
General
Full URL
https://tags.crwdcntrl.net/c/14413/cc.js?ver=1.4&ns=_cc14413
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_256_GCM
Server
93.184.220.113 London, United Kingdom, ASN15133 (EDGECAST - MCI Communications Services, Inc. d/b/a Verizon Business, US),
Reverse DNS
Software
ECS (fcn/40E9) /
Resource Hash
207775987f53f3b91160546806345706ec562f294cb076637004e36d81ef221b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 12 Sep 2019 01:01:17 GMT
server
ECS (fcn/40E9)
etag
"5d7998dd-9b68+gzip"
vary
Accept-Encoding
x-cache
HIT
content-type
application/javascript
status
200
cache-control
max-age=86400
content-length
11493
expires
Sat, 28 Sep 2019 04:34:21 GMT
digest.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/
16 KB
5 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/digest.min.js?ver=2.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
b3c617e4ee00489d6fb85a53bd88cb1e1f5e71ae5244c54a7fea6b6e7d9921ad

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Wed, 22 May 2019 09:37:40 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5ce51864-3fc1"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
UtilityMove-custom.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/
2 KB
1 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
cffef365e4b53f1a6e9d33a7d42c0d1542b573360f774069589240f75f0e84f1

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-751"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
polyfill.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/js/frontend/
102 KB
35 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/js/frontend/polyfill.min.js?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
59173f786dd1f3802f7ab26fd339aac4099dc10c6cb54a6a92213e6af277592a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-19873"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
gpt.js
www.googletagservices.com/tag/js/
44 KB
14 KB
Script
General
Full URL
https://www.googletagservices.com/tag/js/gpt.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
d80e5839d198279a97915c6ca1069c537210b27ab7327b12aca428639134e0c9
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"291 / 950 of 1000 / last-modified: 1569527018"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=900, stale-while-revalidate=3600
timing-allow-origin
*
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
14244
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:21 GMT
adtracking.js
s3.amazonaws.com/haymarket-adtracking-js/prod/
19 KB
19 KB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.216.171.93 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
822847109c3aaf484affe599900514bcf4167ceda17fcca7a97b691d780dae25

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Last-Modified
Tue, 15 Jan 2019 22:54:19 GMT
Server
AmazonS3
x-amz-request-id
BD7F21F8F878E036
ETag
"dc289fc811d6d3a62b068bfcda1f8f30"
Content-Type
application/javascript
x-amz-version-id
MlU6AsBGwcOjZYgQIgNYntESpQyo9BbN
Accept-Ranges
bytes
Content-Length
19158
x-amz-id-2
3lbhrQR4l+Gt7C5DLZ9dNfgeuOTzA9y9ccBjrh3Ou3v65rU7VFwm+XTg0ki5V4UBXbxsoHwIWgA=
head.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
44 KB
13 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/head.min.js?ver=1569414182
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
3463d937369067ba4b7700dd056500a6d9d28fed29addce4e3bce87a0970a348

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Wed, 25 Sep 2019 12:23:02 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d8b5c26-aebf"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
MPR-logo_website.png
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/
16 KB
16 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/MPR-logo_website.png
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
9c9401c3de840fa118289641c41b6125ca5825612d110a20584d2ba32036a1cf
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
etag
"452a9f099947d43a38734d72a92e9193"
last-modified
Wed, 20 Mar 2019 21:55:07 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-frame-options
SAMEORIGIN
x-cache
HIT
content-type
image/png
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
16492
expires
Sat, 19 Oct 2019 17:44:58 GMT
gtm.js
www.googletagmanager.com/
139 KB
34 KB
Script
General
Full URL
https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::2008 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
b92a2e8779df445c71f7253608ef7526db31a5cfda1130a0df33c5e2f554f344
Security Headers
Name Value
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
br
last-modified
Fri, 27 Sep 2019 03:00:00 GMT
server
Google Tag Manager
access-control-allow-headers
Cache-Control
status
200
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
http://www.googletagmanager.com
cache-control
private, max-age=900
access-control-allow-credentials
true
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
35074
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:21 GMT
Park_Brian-150x150.jpg
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/05/
15 KB
15 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/05/Park_Brian-150x150.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
de709acbe98dba4f2f3fc3204a09a5add553a366b33501d54f78b5f263775785
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
etag
"5c39283ae49b2ce7914cb7d8d198c8a8"
last-modified
Tue, 20 Aug 2019 07:11:14 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-frame-options
SAMEORIGIN
x-cache
HIT
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
14921
expires
Tue, 22 Oct 2019 18:17:06 GMT
intravenousdripss108687530_1303955.jpg
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/
15 KB
15 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2018/12/intravenousdripss108687530_1303955.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
1d4ef624c2ebbcfb783d016e932ce5416217aa2eb3f83d0fb8b7ef9828c33b8d
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
etag
"b84d02a8e235a2dac542c3b1a4d55dca"
last-modified
Wed, 20 Mar 2019 09:15:23 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-frame-options
SAMEORIGIN
x-cache
MISS
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
15215
expires
Sun, 27 Oct 2019 04:34:22 GMT
300x100mprsub-300x105.gif
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/01/
13 KB
14 KB
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/uploads/sites/7/2019/01/300x100mprsub-300x105.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
f0341fe392815f4fedec6d94398334b176ce2fb0eafebc391a82afcb3cc5fef0
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
etag
"fb86d90a5bcf340b8bd64802ec39a7a5"
last-modified
Wed, 20 Mar 2019 09:05:43 GMT
server
NetDNA-cache/2.2
x-amz-server-side-encryption
AES256
x-frame-options
SAMEORIGIN
x-cache
HIT
content-type
image/gif
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
13667
expires
Sat, 19 Oct 2019 17:49:13 GMT
spinner.svg
www.empr.com/wp-content/themes/haymarket/assets/svg/src/
694 B
631 B
Image
General
Full URL
https://www.empr.com/wp-content/themes/haymarket/assets/svg/src/spinner.svg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
abb1dd7905b3797711e15609800d43cabead4c0358dc0030a1932a20e82a37d7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
nginx
status
200
etag
W/"5c99e3ee-2b6"
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding
content-type
image/svg+xml
access-control-allow-origin
*
cache-control
public, max-age=31536000
96ac8580a54c3864c4ba15ff4a38efdcb7084985-v2.js
content.maropost.com/uploads/1323/websites/5/
3 KB
3 KB
Script
General
Full URL
https://content.maropost.com/uploads/1323/websites/5/96ac8580a54c3864c4ba15ff4a38efdcb7084985-v2.js?ver=1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:1c00:1b:fadc:b780:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
AmazonS3 /
Resource Hash
3b8eec5229515f9e95a68b635aba1d27d7d91f2e1b726302c53124fe18cefd20

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 23 Sep 2019 19:08:41 GMT
via
1.1 c4ada86230c95b165d889d1f1d10389d.cloudfront.net (CloudFront)
last-modified
Thu, 27 Sep 2018 21:48:02 GMT
server
AmazonS3
age
31150
etag
"ff4375eccda3ca6bc54ed96c5d77d9bb"
x-cache
Hit from cloudfront
status
200
x-amz-cf-pop
FRA56
accept-ranges
bytes
content-length
2622
x-amz-cf-id
N7yXJ36I8XYZkkzpuJLPNA3tJbpY84H1Ek6xg96i2CIL-0VOmWE9GA==
blocks.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
7 KB
3 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/blocks.min.js?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
3ed3de3fd0fabc795d8b96ada205998944ff3157366f20b70d5d10b099b63120

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-1b42"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
local-storage-lib.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/
1 KB
918 B
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/local-storage-lib.js?ver=2.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
693d39f8b27d78f2a570672b862512cb8e3dee72e8f641cf95ada2d81bac720b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
last-modified
Wed, 17 Jul 2019 13:03:16 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d2f1c94-591"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
npi-manager.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/
3 KB
1 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/hm-npi-manager/js/npi-manager.js?ver=2.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
43a5ba666207ae3718ce7fe6b4015c58043b4ac4dfdacae285d5d8574d80fdf6

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-b3b"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
hmi-registration-ui.manifest.js
s3.amazonaws.com/haymarket-reg-js/develop/production/
799 B
1 KB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.manifest.js?ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.216.171.93 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
4d3e9dbf75d761b4fc344b3be601971eb517ce533c7ce46e093539e03349616e

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Last-Modified
Thu, 29 Aug 2019 20:10:10 GMT
Server
AmazonS3
x-amz-request-id
1F2F91DB93CB9D65
ETag
"6878a8fbe72bde4a3f8ecf5b16523972"
Content-Type
application/javascript
x-amz-version-id
csLBKnYjTffo31CifRF6x383B2E_amuJ
Accept-Ranges
bytes
Content-Length
799
x-amz-id-2
vaRSYJ+PNPk/zi4hvlOoE11BGaR5zr1+4mDDaXmV4iicnfYhr7zOPsYGED+Roxf/phQ71CEI+f4=
hmi-registration-ui.vendor.js
s3.amazonaws.com/haymarket-reg-js/develop/production/
357 KB
357 KB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.216.171.93 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
2673f6b0416b9a9f7488ee96f384f5badfa04acb14499c92ae52e394b7572f1f

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Last-Modified
Thu, 29 Aug 2019 20:10:10 GMT
Server
AmazonS3
x-amz-request-id
C8372B5AC5FB85F8
ETag
"dfdfd93abc9eec4ff346a12a61df7c41"
Content-Type
application/javascript
x-amz-version-id
6ACuZZ4Fakkhaw3IL9mD952B0XZGZK4Q
Accept-Ranges
bytes
Content-Length
365119
x-amz-id-2
rqHMumRZMfhLItk5BcyITLrrDdQsOaB8V/IDOuuvDjgtLhwPVALe8OojXNlBYCcEEzNts/K+jF8=
hmi-registration-ui.bundle.js
s3.amazonaws.com/haymarket-reg-js/develop/production/
1 MB
1 MB
Script
General
Full URL
https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.bundle.js?ver=0.1.1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.216.171.93 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
s3-1.amazonaws.com
Software
AmazonS3 /
Resource Hash
4eef9cbbcb01ac2538e54c45514c0560e686abf17070adfba489fd1b3b86455a

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Last-Modified
Thu, 29 Aug 2019 20:10:10 GMT
Server
AmazonS3
x-amz-request-id
8E7B5299E63DD905
ETag
"8f47379688c3f5980d42b891fcaea0eb"
Content-Type
application/javascript
x-amz-version-id
1g9qbXhjK6v_p1EyiVTzg_c7stFBXUFD
Accept-Ranges
bytes
Content-Length
1225121
x-amz-id-2
vF4Fp4whhohcGqh2Z6qlGlDfSYRI2DlbBCRmHyO930sv67pE8N2AHfhWQ61VfI982VDlEBm3yZ4=
autosuggest.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/js/
17 KB
5 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/plugins/elasticpress/dist/js/autosuggest.min.js?ver=3.1.4
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
6258dbe6dbce7a7de872ad56d9ceea8354f5d37626e66201ec29b2717a95e949

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 12 Sep 2019 09:51:52 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d7a1538-4361"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
frontend.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
147 KB
39 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
be6beaacd90961241ca111e54c0953bc476a844a264e5afade4792a75c78c540

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 12 Sep 2019 09:51:52 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d7a1538-24c66"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
iab.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/
8 KB
2 KB
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
6463301e10c71f76fc14bb977dfa9097b5633ed4a3ee4119abccf2ead9aa9e29

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 29 Aug 2019 13:28:17 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5d67d2f1-1ecd"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
wp-embed.min.js
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/
1 KB
1004 B
Script
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/wp-embed.min.js?ver=5.2.3
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
2152557cac69e2bd7d6debef5037a9f554f9209cc305b8141b3329acb10c42b7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
last-modified
Thu, 30 Aug 2018 12:40:26 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5b87e5ba-57b"
vary
Accept-Encoding, Accept-Encoding
x-cache
HIT
content-type
application/javascript
access-control-allow-origin
*
cache-control
public, max-age=31536000
integrator.js
adservice.google.de/adsid/
109 B
171 B
Script
General
Full URL
https://adservice.google.de/adsid/integrator.js?domain=www.empr.com
Requested by
Host: www.googletagservices.com
URL: https://www.googletagservices.com/tag/js/gpt.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
0482a98d09daebc18a0d2e1ed8f748da5b0179e61223ed541101df1f4699f073
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
cafe
p3p
CP="This is not a P3P policy! See http://support.google.com/accounts/answer/151657 for more info."
status
200
cache-control
private, no-cache, no-store
content-disposition
attachment; filename="f.txt"
content-type
application/javascript; charset=UTF-8
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
104
x-xss-protection
0
integrator.js
adservice.google.com/adsid/
109 B
171 B
Script
General
Full URL
https://adservice.google.com/adsid/integrator.js?domain=www.empr.com
Requested by
Host: www.googletagservices.com
URL: https://www.googletagservices.com/tag/js/gpt.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
0482a98d09daebc18a0d2e1ed8f748da5b0179e61223ed541101df1f4699f073
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Fri, 27 Sep 2019 04:34:21 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
cafe
p3p
CP="This is not a P3P policy! See http://support.google.com/accounts/answer/151657 for more info."
status
200
cache-control
private, no-cache, no-store
content-disposition
attachment; filename="f.txt"
content-type
application/javascript; charset=UTF-8
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
104
x-xss-protection
0
pubads_impl_2019091901.js
securepubads.g.doubleclick.net/gpt/
156 KB
57 KB
Script
General
Full URL
https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Requested by
Host: www.googletagservices.com
URL: https://www.googletagservices.com/tag/js/gpt.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
sffe /
Resource Hash
c77635c1d346c5471d294f59d0c4ef11f71c21f94e82087cbd99984c9aaa3cda
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Thu, 19 Sep 2019 13:07:51 GMT
server
sffe
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, immutable, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
58568
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:22 GMT
7341.js
script.crazyegg.com/pages/scripts/0034/
88 KB
28 KB
Script
General
Full URL
https://script.crazyegg.com/pages/scripts/0034/7341.js?435988
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700::6813:9308 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
8617f3b621a7fe14ab36ef607fda9909163c458e72f24f0836fb0158a5e31f83

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
via
1.1 04ce5a607a98db6d08257633417b84d7.cloudfront.net (CloudFront)
cf-cache-status
HIT
age
2133
cf-polished
origSize=89761
x-cache
Hit from cloudfront
status
200
content-encoding
gzip
last-modified
Wed, 25 Sep 2019 17:06:18 GMT
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/x-javascript
cache-control
private, max-age=300
x-amz-cf-pop
FRA2-C2
cf-ray
51cac3c90876cbb0-VIE
x-amz-cf-id
bgSABxQQehjngADKxBsDyOjIDQya34o6WaHTLGcNWBLISn9j59kvLw==
cf-bgj
minify
analytics.js
www.google-analytics.com/
43 KB
17 KB
Script
General
Full URL
https://www.google-analytics.com/analytics.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:815::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
dbb67c620eaabf6679a314db18d3ae43037aef71ab27422e6feec08ee987cc0a
Security Headers
Name Value
Strict-Transport-Security max-age=10886400; includeSubDomains; preload
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=10886400; includeSubDomains; preload
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Mon, 19 Aug 2019 17:22:41 GMT
server
Golfe2
age
504
date
Fri, 27 Sep 2019 04:25:58 GMT
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
public, max-age=7200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
17803
expires
Fri, 27 Sep 2019 06:25:58 GMT
b2
sb.scorecardresearch.com/
Redirect Chain
  • https://sb.scorecardresearch.com/b?c1=2&c2=21948019&ns__t=1569558861891&ns_c=UTF-8&c8=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&c7=https%...
  • https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1569558861891&ns_c=UTF-8&c8=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&c7=https...
0
248 B
Image
General
Full URL
https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1569558861891&ns_c=UTF-8&c8=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&c9=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
2.19.43.224 , Ascension Island, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS
a2-19-43-224.deploy.static.akamaitechnologies.com
Software
/
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:22 GMT
Cache-Control
private, no-cache, no-cache=Set-Cookie, no-store, proxy-revalidate
Connection
keep-alive
Content-Length
0
Expires
Mon, 01 Jan 1990 00:00:00 GMT

Redirect headers

Location
https://sb.scorecardresearch.com/b2?c1=2&c2=21948019&ns__t=1569558861891&ns_c=UTF-8&c8=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&c7=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&c9=
Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:22 GMT
Cache-Control
private, no-cache, no-cache=Set-Cookie, no-store, proxy-revalidate
Connection
keep-alive
Content-Length
0
Expires
Mon, 01 Jan 1990 00:00:00 GMT
src.svg
www.empr.com/wp-content/themes/haymarket/assets/svg/
33 KB
10 KB
Other
General
Full URL
https://www.empr.com/wp-content/themes/haymarket/assets/svg/src.svg?ver=1553589230
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
866e74600600f8647c979414828f3538d646101dc8504de84c2ed00e30460811

Request headers

Sec-Fetch-Mode
same-origin
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
nginx
status
200
etag
W/"5c99e3ee-8317"
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding
content-type
image/svg+xml
access-control-allow-origin
*
cache-control
public, max-age=31536000
S6uyw4BMUTPHjx4wXiWtFCc.woff2
fonts.gstatic.com/s/lato/v16/
14 KB
14 KB
Font
General
Full URL
https://fonts.gstatic.com/s/lato/v16/S6uyw4BMUTPHjx4wXiWtFCc.woff2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
036d841b132c14046e26d8f2da1bc634c6ad34885ed1295660694a91c98933a6
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 26 Aug 2019 13:36:09 GMT
x-content-type-options
nosniff
last-modified
Tue, 23 Jul 2019 03:45:55 GMT
server
sffe
age
2732293
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
14044
x-xss-protection
0
expires
Tue, 25 Aug 2020 13:36:09 GMT
chevron-right-white.svg
1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/svg/src/
190 B
400 B
Image
General
Full URL
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/svg/src/chevron-right-white.svg
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
94.31.29.64 , United Kingdom, ASN33438 (HIGHWINDS2 - Highwinds Network Group, Inc., US),
Reverse DNS
94.31.29.64.IPYX-077437-ZYO.above.net
Software
NetDNA-cache/2.2 /
Resource Hash
8e0da2e2d764c1a202d33dd39287784df8ac6bc20c7401ea14f2d62001292856

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/css/style.min.css?ver=1567085297
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
last-modified
Tue, 26 Mar 2019 08:33:50 GMT
server
NetDNA-cache/2.2
status
200
etag
W/"5c99e3ee-be"
vary
Accept-Encoding
x-cache
HIT
content-type
image/svg+xml
access-control-allow-origin
*
cache-control
public, max-age=31536000
BngRUXZYTXPIvIBgJJSb6u92w7CGwR2oefDo.woff2
fonts.gstatic.com/s/robotoslab/v9/
11 KB
11 KB
Font
General
Full URL
https://fonts.gstatic.com/s/robotoslab/v9/BngRUXZYTXPIvIBgJJSb6u92w7CGwR2oefDo.woff2
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
4901c9453014d8e210b2f62189f68c2d7964543517e1fc8447924de7d542058a
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 26 Aug 2019 13:27:01 GMT
x-content-type-options
nosniff
last-modified
Mon, 22 Jul 2019 19:27:03 GMT
server
sffe
age
2732841
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
11388
x-xss-protection
0
expires
Tue, 25 Aug 2020 13:27:01 GMT
BngMUXZYTXPIvIBgJJSb6ufN5qWr4xCC.woff2
fonts.gstatic.com/s/robotoslab/v9/
11 KB
11 KB
Font
General
Full URL
https://fonts.gstatic.com/s/robotoslab/v9/BngMUXZYTXPIvIBgJJSb6ufN5qWr4xCC.woff2
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/assets/vendor/UtilityMove-custom.min.js?ver=1553589230
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
c68d891f07355e5d0807b4a4f18ac8f16f6e9088277be3134c7efa570022ab2d
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Mon, 02 Sep 2019 15:53:22 GMT
x-content-type-options
nosniff
last-modified
Mon, 22 Jul 2019 19:19:23 GMT
server
sffe
age
2119260
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
11272
x-xss-protection
0
expires
Tue, 01 Sep 2020 15:53:22 GMT
S6u9w4BMUTPHh6UVSwiPGQ3q5d0.woff2
fonts.gstatic.com/s/lato/v16/
14 KB
14 KB
Font
General
Full URL
https://fonts.gstatic.com/s/lato/v16/S6u9w4BMUTPHh6UVSwiPGQ3q5d0.woff2
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
9baad10e85c5be8d5697086479983b6b477197103bf8f0f11817b1bdfb9a7451
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://fonts.googleapis.com/css?family=Lato:400,400i,700,700i|Roboto+Slab:400,400i,700,700i
Origin
https://www.empr.com
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Wed, 21 Aug 2019 21:19:20 GMT
x-content-type-options
nosniff
last-modified
Tue, 23 Jul 2019 03:45:54 GMT
server
sffe
age
3136502
status
200
content-type
font/woff2
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
14176
x-xss-protection
0
expires
Thu, 20 Aug 2020 21:19:20 GMT
js
www.google-analytics.com/gtm/
56 KB
21 KB
Script
General
Full URL
https://www.google-analytics.com/gtm/js?id=GTM-T8P2ZZ9&t=gtm1&cid=408063271.1569558862
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:815::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Google Tag Manager /
Resource Hash
2b9d553068a82437949fb7f332ecf746c87fb1a8abedf7dc231a6026030f5c38
Security Headers
Name Value
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
br
last-modified
Fri, 27 Sep 2019 03:00:00 GMT
server
Google Tag Manager
access-control-allow-headers
Cache-Control
status
200
vary
Accept-Encoding
content-type
application/javascript; charset=UTF-8
access-control-allow-origin
http://www.googletagmanager.com
cache-control
private, max-age=900
access-control-allow-credentials
true
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
21298
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:22 GMT
atrk.js
d31qbv1cthcecs.cloudfront.net/
4 KB
2 KB
Script
General
Full URL
https://d31qbv1cthcecs.cloudfront.net/atrk.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.38 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-38.fra53.r.cloudfront.net
Software
AmazonS3 /
Resource Hash
90451ba3e82cd9db02f0ca76bd45d0ab5ef7e90a49da4215903cb7f08471e2e7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Tue, 04 Jun 2019 00:38:41 GMT
Content-Encoding
gzip
Connection
keep-alive
Last-Modified
Sat, 16 Mar 2019 16:01:33 GMT
Server
AmazonS3
Age
9950142
Vary
Accept-Encoding
X-Cache
Hit from cloudfront
Content-Type
text/javascript
Via
1.1 e7377cc861b31102786678df3616bf69.cloudfront.net (CloudFront)
Cache-Control
max-age=26920000
Transfer-Encoding
chunked
X-Amz-Cf-Pop
FRA53-C1
X-Amz-Cf-Id
bl_yHHWpAkOihaAJ32WYt2RSDg4usAJFKLupWrIIqVxJl4KrXOiksQ==
gg.js
sb.scorecardresearch.com/rs/pt/
2 KB
1 KB
Script
General
Full URL
https://sb.scorecardresearch.com/rs/pt/gg.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
2.19.43.224 , Ascension Island, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS
a2-19-43-224.deploy.static.akamaitechnologies.com
Software
/
Resource Hash
d0e90581c7b707bcad9f78f9b066371e6b1377d993ff03cbdee7193d6068ac78

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Content-Encoding
gzip
Connection
keep-alive
X-N
S
Content-Length
1246
Vary
Accept-Encoding
Content-Type
application/x-javascript
fbevents.js
connect.facebook.net/en_US/
121 KB
31 KB
Script
General
Full URL
https://connect.facebook.net/en_US/fbevents.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f01c:8012:face:b00c:0:3 , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
/
Resource Hash
14d88b3a27f0e6de034f86ad42d6411081e9467daf754147f2f16bcb20782177
Security Headers
Name Value
Content-Security-Policy default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self';
Strict-Transport-Security max-age=31536000; preload; includeSubDomains
X-Content-Type-Options nosniff
X-Frame-Options DENY
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000; preload; includeSubDomains
content-encoding
gzip
x-content-type-options
nosniff
status
200
content-length
31604
x-xss-protection
0
pragma
public
x-fb-debug
Dw14h4pXG7zLzJuoCovGMDTXgTrHT2Ny2NKKk4kL2Gbly48s1WFeUi18NsgEGsq82qo9S2gWlNkiImjmhZk5tA==
x-fb-trip-id
194532234
x-frame-options
DENY
date
Fri, 27 Sep 2019 04:34:22 GMT
vary
Origin, Accept-Encoding
access-control-allow-methods
OPTIONS
content-type
application/x-javascript; charset=utf-8
access-control-allow-origin
https://connect.facebook.net
access-control-expose-headers
X-FB-Debug, X-Loader-Length
cache-control
public, max-age=1200
access-control-allow-credentials
true
content-security-policy
default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self';
expires
Sat, 01 Jan 2000 00:00:00 GMT
i
sp.sitomobile.com/
Redirect Chain
  • https://mt.sitomobile.com/sync/ta?aid=136&sid=hmm&val=12
  • https://pixel.tapad.com/idsync/ex/push?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12
  • https://pixel.tapad.com/idsync/ex/push/check?partner_id=2822&partner_url=https%3A%2F%2Fmt.sitomobile.com%2Fsync%2Ftacb%3Fexid%3D%24%7BTA_DEVICE_ID%7D%26aid%3D136%26sid%3Dhmm%26val%3D12
  • https://mt.sitomobile.com/sync/tacb?exid=141afd41-e0e0-11e9-8dcb-52c7686934ad&aid=136&sid=hmm&val=12
  • https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5...
43 B
388 B
Script
General
Full URL
https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L2Nvb2tpZV9zeW5jL2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InBhcnRuZXJJZCI6InRhcGFkIn19fQ%3D%3D&cx=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
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.225.65.223 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-225-65-223.compute-1.amazonaws.com
Software
Apache-Coyote/1.1 /
Resource Hash
f4eef8263281c0b26486637831251059757bc3fdc4c3a48045a8ef8646b36e8f

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Server
Apache-Coyote/1.1
Connection
keep-alive
P3P
policyref="/w3c/p3p.xml", CP="NOI DSP COR NID PSA OUR IND COM NAV STA"
Content-Length
43
Content-Type
image/gif

Redirect headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Server
nginx/1.12.1
X-Powered-By
Express
Vary
Accept
Content-Type
text/plain; charset=utf-8
Location
https://sp.sitomobile.com/i?tna=sito&p=mob&e=ue&ue_px=eyJzY2hlbWEiOiJpZ2x1OmNvbS5zbm93cGxvd2FuYWx5dGljcy5zbm93cGxvdy91bnN0cnVjdF9ldmVudC9qc29uc2NoZW1hLzEtMC0wIiwiZGF0YSI6eyJzY2hlbWEiOiJpZ2x1OmNvbS5zaXRvbW9iaWxlLnNub3dwbG93L2Nvb2tpZV9zeW5jL2pzb25zY2hlbWEvMS0wLTAiLCJkYXRhIjp7InBhcnRuZXJJZCI6InRhcGFkIn19fQ%3D%3D&cx=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
Connection
keep-alive
Content-Length
972
up_loader.1.1.0.js
js.adsrvr.org/
6 KB
2 KB
Script
General
Full URL
https://js.adsrvr.org/up_loader.1.1.0.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.207.113 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-207-113.fra53.r.cloudfront.net
Software
AmazonS3 /
Resource Hash
7e98e381189d908e1981b6e535bcdd7f3edceafdb0e7095f3e04292e8aac6a0c

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 26 Sep 2019 19:04:49 GMT
Content-Encoding
gzip
Last-Modified
Wed, 17 Jul 2019 18:26:10 GMT
Server
AmazonS3
Age
34270
Vary
Accept-Encoding
X-Cache
Hit from cloudfront
Content-Type
application/x-javascript
Via
1.1 f8895de4463e8d120a0f4b4a1f7703e4.cloudfront.net (CloudFront)
Connection
keep-alive
Transfer-Encoding
chunked
X-Amz-Cf-Pop
FRA53-C1
X-Amz-Cf-Id
FsUiLhbq5bTilWTHM2TZ3imqV6JQNIkzCYFuaKAdDJheBmobdfoUsQ==
96ac8580a54c3864c4ba15ff4a38efdcb7084985.js
mpct1.maropost.com/accounts/1323/websites/5/track/
4 KB
3 KB
Script
General
Full URL
https://mpct1.maropost.com/accounts/1323/websites/5/track/96ac8580a54c3864c4ba15ff4a38efdcb7084985.js?contact_id=2303653&campaign_id=68826&title=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&url=https%3A%2F%2Fempr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F&parent_url=&version=2&&&&funnel[0][name]=&funnel[0][status]=started&funnel[0][time_out]=40&
Requested by
Host: content.maropost.com
URL: https://content.maropost.com/uploads/1323/websites/5/96ac8580a54c3864c4ba15ff4a38efdcb7084985-v2.js?ver=1.1
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.238.92.4 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
4.92.238.35.bc.googleusercontent.com
Software
nginx/1.14.0 + Phusion Passenger 5.3.4 / Phusion Passenger 5.3.4
Resource Hash
e36ed3048605fc75a0274f4c53ca175ef750a014e9cd3ce1cefdb734b50bf148
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Frame-Options SAMEORIGIN
X-Xss-Protection 1; mode=block

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Content-Encoding
gzip
X-Content-Type-Options
nosniff
X-Powered-By
Phusion Passenger 5.3.4
Transfer-Encoding
chunked
Status
200 OK
Connection
keep-alive
Vary
Accept-Encoding
X-XSS-Protection
1; mode=block
X-Request-Id
3d58ff89-0a37-4b83-9fda-de573d39c343
X-Runtime
0.026833
Server
nginx/1.14.0 + Phusion Passenger 5.3.4
ETag
W/"2f15ea67e7535ce59aea4dd091090af3"
X-Frame-Options
SAMEORIGIN
Content-Type
text/javascript; charset=utf-8
Cache-Control
max-age=0, private, must-revalidate
lio.js
c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/
45 KB
11 KB
Script
General
Full URL
https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
803e3ba42413340bcc0c185e1b5f40bfcc115ed3a52832ffcdf7827cbf239be0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
51cac3c9acdf5a06-VIE
date
Fri, 27 Sep 2019 04:34:22 GMT
via
1.1 google
cf-cache-status
HIT
server
cloudflare
age
34
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Fri, 27 Sep 2019 06:34:22 GMT
most-widget
www.empr.com/wp-json/haymarket/v1/
4 KB
2 KB
XHR
General
Full URL
https://www.empr.com/wp-json/haymarket/v1/most-widget?id=most-5
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
169b598c2a86576823e1068924ba6325c973d3250c9464ff3ea0e0fcbd73cf01
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
x-content-type-options
nosniff
x-cacheable
SHORT
x-cache
HIT: 1
status
200
x-wpengine-segment
NONHT
x-cache-group
normal
access-control-allow-headers
Authorization, Content-Type
allow
GET
server
nginx
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie
content-type
application/json; charset=UTF-8
access-control-expose-headers
X-WP-Total, X-WP-TotalPages
cache-control
max-age=600, must-revalidate
x-distributor
yes
x-robots-tag
noindex
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/"
x-pass-why
124026
www.empr.com/wp-json/haymarket/v1/infinite-scroll/
10 KB
3 KB
XHR
General
Full URL
https://www.empr.com/wp-json/haymarket/v1/infinite-scroll/124026
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
a9be45a787fc403ee16bf5376a2cf856c1094586c8a519cb1f864ac0137d36f6
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
x-content-type-options
nosniff
x-cacheable
SHORT
x-cache
MISS
status
200
x-wpengine-segment
NONHT
x-cache-group
normal
access-control-allow-headers
Authorization, Content-Type
allow
GET
server
nginx
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie
content-type
application/json; charset=UTF-8
access-control-expose-headers
X-WP-Total, X-WP-TotalPages
cache-control
max-age=600, must-revalidate
x-distributor
yes
x-robots-tag
noindex
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/"
x-pass-why
partial-login
www.empr.com/wp-json/haymarket/v1/
634 B
839 B
XHR
General
Full URL
https://www.empr.com/wp-json/haymarket/v1/partial-login?subid=&subemail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
ad16911f49d3e72d789bfe438841576129e86d69f42bcaddf489d3523ed69951
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
content-encoding
gzip
x-content-type-options
nosniff
x-cacheable
SHORT
x-cache
HIT: 2
status
200
x-wpengine-segment
NONHT
x-cache-group
normal
access-control-allow-headers
Authorization, Content-Type
allow
GET
server
nginx
vary
Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie
content-type
application/json; charset=UTF-8
access-control-expose-headers
X-WP-Total, X-WP-TotalPages
cache-control
max-age=600, must-revalidate
x-distributor
yes
x-robots-tag
noindex
link
<https://www.empr.com/wp-json/>; rel="https://api.w.org/"
x-pass-why
/
accounts.haymarketmedia.com/sso/check/
45 B
440 B
XHR
General
Full URL
https://accounts.haymarketmedia.com/sso/check/?gn=101
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.192.84.248 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-192-84-248.compute-1.amazonaws.com
Software
Microsoft-IIS/8.5 / ASP.NET
Resource Hash
916b46685de3064525220ba828d946e60ab332f5e65c62d7df5fe9877f9c54b2

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
x-aspnetmvc-version
4.0
server
Microsoft-IIS/8.5
x-aspnet-version
4.0.30319
x-powered-by
ASP.NET
status
200
content-type
application/json; charset=utf-8
access-control-allow-origin
https://www.empr.com
cache-control
private
access-control-allow-credentials
true
content-length
45
1073716492693685
connect.facebook.net/signals/config/
307 KB
78 KB
Script
General
Full URL
https://connect.facebook.net/signals/config/1073716492693685?v=2.9.4&r=stable
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f01c:8012:face:b00c:0:3 , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
/
Resource Hash
93c4a8cc5d4782ed85c9a7661ce68d1e7e7e6d4a91a57219f649f77564617460
Security Headers
Name Value
Content-Security-Policy default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' chrome-extension://boadgeojelhgndaghljhdicfkmllpafd chrome-extension://dliochdbjfkdbacpmhlcpmleaejidimm;
Strict-Transport-Security max-age=31536000; preload; includeSubDomains
X-Content-Type-Options nosniff
X-Frame-Options DENY
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000; preload; includeSubDomains
content-encoding
gzip
x-content-type-options
nosniff
status
200
content-length
79754
x-xss-protection
0
pragma
public
x-fb-debug
Ku771L1PPOlMX6ACX8Ai+wlgNEMQ+OmItIGFAKU6CFe38MrnRjvfOgU2juYJdkG+V+Y+jdyn+OK3seTRBNmzBA==
x-fb-trip-id
194532234
x-frame-options
DENY
date
Fri, 27 Sep 2019 04:34:22 GMT
vary
Origin, Accept-Encoding
access-control-allow-methods
OPTIONS
content-type
application/x-javascript; charset=utf-8
access-control-allow-origin
https://connect.facebook.net
access-control-expose-headers
X-FB-Debug, X-Loader-Length
cache-control
public, max-age=1200
access-control-allow-credentials
true
content-security-policy
default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' chrome-extension://boadgeojelhgndaghljhdicfkmllpafd chrome-extension://dliochdbjfkdbacpmhlcpmleaejidimm;
expires
Sat, 01 Jan 2000 00:00:00 GMT
atrk.gif
certify.alexametrics.com/
43 B
552 B
Image
General
Full URL
https://certify.alexametrics.com/atrk.gif?frame_height=1200&frame_width=1600&iframe=0&title=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&time=1569558862356&time_zone_offset=-120&screen_params=1600x1200x24&java_enabled=0&cookie_enabled=1&ref_url=&host_url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&random_number=3386785382&sess_cookie=56eed28316d70ff9a13e51fc8b3&sess_cookie_flag=1&user_cookie=56eed28316d70ff9a13e51fc8b3&user_cookie_flag=1&dynamic=true&domain=empr.com&account=gujPp1NErb205V&jsv=20130128&user_lang=en-US
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.3 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-3.fra53.r.cloudfront.net
Software
AmazonS3 /
Resource Hash
89fe0ee6020314794fc2cfeacf3d10c31050cfe56f8ebddf1ed0a33fbe941fa7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Thu, 26 Sep 2019 21:18:04 GMT
Via
1.1 16dc09493f48bbc1fd2cdd6e175a94f7.cloudfront.net (CloudFront)
Last-Modified
Mon, 17 Jan 2011 20:41:40 GMT
Server
AmazonS3
Age
26179
ETag
"221d8352905f2c38b3cb2bd191d630b0"
X-Cache
Hit from cloudfront
Content-Type
image/gif
Connection
keep-alive
Accept-Ranges
bytes
X-Amz-Cf-Pop
FRA53-C1
x-amz-meta-alexa-last-modified
20110117123941
Content-Length
43
X-Amz-Cf-Id
ge129ourCXjpK4LdD7l2ELAnQKF00UnWecnLGIbE6NiQqtG2euVmsg==
io.min.js
c.lytics.io/static/v2/
13 KB
6 KB
Script
General
Full URL
https://c.lytics.io/static/v2/io.min.js
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
1c0e0ca6ba3ee267ba14d39184efb68c958717fc6e58b528b700502c0aea5170

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
51cac3c9dcf25a06-VIE
date
Fri, 27 Sep 2019 04:34:22 GMT
via
1.1 google
cf-cache-status
HIT
last-modified
Fri, 13 Sep 2019 19:02:47 GMT
server
cloudflare
age
6616
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Fri, 27 Sep 2019 06:34:22 GMT
beacon.js
www.medtargetsystem.com/javascript/
176 KB
52 KB
Script
General
Full URL
https://www.medtargetsystem.com/javascript/beacon.js?v2.5.12
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) /
Resource Hash
ca5bf9816a06a54b2361b4a16e34d69dde1768182c8dcf28d36b5f1c761ad2dc

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Content-Encoding
gzip
Last-Modified
Fri, 06 Sep 2019 19:13:49 GMT
Server
Apache/2.4.7 (Ubuntu)
ETag
"2c0a2-591e73cea1540-gzip"
Vary
X-Forwarded-Proto,Accept-Encoding
Content-Type
application/javascript
Connection
keep-alive
Accept-Ranges
bytes
Content-Length
52823
linkid.js
www.google-analytics.com/plugins/ua/
2 KB
925 B
Script
General
Full URL
https://www.google-analytics.com/plugins/ua/linkid.js
Requested by
Host: www.google-analytics.com
URL: https://www.google-analytics.com/analytics.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:815::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
92fca55833f48b4289ac8f1cedd48752b580fce4ec4b5d81670b8193d6e51b54
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 03:40:29 GMT
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Thu, 21 Apr 2016 03:17:22 GMT
server
sffe
age
3233
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
public, max-age=3600
accept-ranges
bytes
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
856
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:40:29 GMT
tag.aspx
ml314.com/
26 KB
12 KB
Script
General
Full URL
https://ml314.com/tag.aspx?2782019
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.252.62.73 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-252-62-73.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
7d655e8cd62ba58d86b3bc9c8e1e04a76506a4dfc852c3b3813deb0aef284548

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Content-Encoding
gzip
Last-Modified
Fri, 27 Sep 2019 04:23:47 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Vary
Accept-Encoding
Content-Type
application/javascript; charset=utf-8
Cache-Control
public, max-age=85764
Connection
keep-alive
Content-Length
11933
Expires
Sat, 28 Sep 2019 04:23:47 GMT
inferredEvents.js
connect.facebook.net/signals/plugins/
35 KB
10 KB
Script
General
Full URL
https://connect.facebook.net/signals/plugins/inferredEvents.js?v=2.9.4
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f01c:8012:face:b00c:0:3 , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
/
Resource Hash
b4e9e9bef19c34422f55a7fdb9d10c4db5e39cff24b8c98a0be0e09b2ee6ac2b
Security Headers
Name Value
Content-Security-Policy default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' chrome-extension://boadgeojelhgndaghljhdicfkmllpafd chrome-extension://dliochdbjfkdbacpmhlcpmleaejidimm;
Strict-Transport-Security max-age=31536000; preload; includeSubDomains
X-Content-Type-Options nosniff
X-Frame-Options DENY
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000; preload; includeSubDomains
content-encoding
gzip
x-content-type-options
nosniff
status
200
content-length
10218
x-xss-protection
0
pragma
public
x-fb-debug
XD+jPKOTQiEcQqY+fZ4lH21OPCoB0kuuo/T8KNiAJxnmL+wH2Q4rOxl9tT8hhgxzejAekplxC2FiCYKXtlMmCQ==
x-fb-trip-id
194532234
x-frame-options
DENY
date
Fri, 27 Sep 2019 04:34:22 GMT
vary
Origin, Accept-Encoding
access-control-allow-methods
OPTIONS
content-type
application/x-javascript; charset=utf-8
access-control-allow-origin
https://connect.facebook.net
access-control-expose-headers
X-FB-Debug, X-Loader-Length
cache-control
public, max-age=1200
access-control-allow-credentials
true
content-security-policy
default-src * data: blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net *.google-analytics.com *.virtualearth.net *.google.com 127.0.0.1:* *.spotilocal.com:* 'unsafe-inline' 'unsafe-eval' blob: data: 'self';style-src data: blob: 'unsafe-inline' *;connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net *.spotilocal.com:* wss://*.facebook.com:* https://fb.scanandcleanlocal.com:* attachment.fbsbx.com ws://localhost:* blob: *.cdninstagram.com 'self' chrome-extension://boadgeojelhgndaghljhdicfkmllpafd chrome-extension://dliochdbjfkdbacpmhlcpmleaejidimm;
expires
Sat, 01 Jan 2000 00:00:00 GMT
ga-audiences
www.google.de/ads/
Redirect Chain
  • https://www.google-analytics.com/r/collect?v=1&_v=j79&a=652718221&t=pageview&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-y...
  • https://stats.g.doubleclick.net/r/collect?v=1&aip=1&t=dc&_r=3&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_gid=2019810217.1569558862&gjid=1546333091&_v=j79&z=68886949
  • https://www.google.com/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_v=j79&z=68886949
  • https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_v=j79&z=68886949&slf_rd=1&random=2208599624
42 B
109 B
Image
General
Full URL
https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_v=j79&z=68886949&slf_rd=1&random=2208599624
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81a::2003 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:22 GMT
x-content-type-options
nosniff
server
cafe
timing-allow-origin
*
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
cache-control
no-cache, no-store, must-revalidate
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
42
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT

Redirect headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:22 GMT
x-content-type-options
nosniff
server
cafe
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
302
content-type
text/html; charset=UTF-8
location
https://www.google.de/ads/ga-audiences?v=1&aip=1&t=sr&_r=4&tid=UA-1290429-2&cid=408063271.1569558862&jid=2034178867&_v=j79&z=68886949&slf_rd=1&random=2208599624
cache-control
no-cache, no-store, must-revalidate
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
0
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
4
c.lytics.io/cid/
78 B
191 B
Script
General
Full URL
https://c.lytics.io/cid/4?callback=jQuery1124023551018991179729_1569558861801&_=1569558861802
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery.js?ver=1.12.4-wp
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
27fe51d679dff35254237de12ba03b0d629cd85e1ae67f74c17cdc973195e933

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
51cac3ca1d045a06-VIE
pragma
no-cache
date
Fri, 27 Sep 2019 04:34:22 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
text/javascript
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
content-encoding
br
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
expires
0
/
www.facebook.com/tr/
44 B
247 B
Image
General
Full URL
https://www.facebook.com/tr/?id=1073716492693685&ev=PageView&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&rl=&if=false&ts=1569558862413&sw=1600&sh=1200&v=2.9.4&r=stable&ec=0&o=30&fbp=fb.1.1569558862412.761924113&it=1569558862354&coo=false&rqm=GET
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f11c:8083:face:b00c:0:25de , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
proxygen-bolt /
Resource Hash
10d8d42d73a02ddb877101e72fbfa15a0ec820224d97cedee4cf92d571be5caa
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:22 GMT
last-modified
Fri, 21 Dec 2012 00:00:01 GMT
server
proxygen-bolt
strict-transport-security
max-age=31536000; includeSubDomains
content-type
image/gif
status
200
cache-control
no-cache, must-revalidate, max-age=0
content-length
44
expires
Fri, 27 Sep 2019 04:34:22 GMT
utsync.ashx
ml314.com/
793 B
2 KB
Script
General
Full URL
https://ml314.com/utsync.ashx?pub=&adv=&et=0&eid=740&ct=js&pi=&fp=&clid=&if=0&ps=&cl=&mlt=&data=&&cp=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&pv=1569558862494_3sp7rkier&bl=en-us&cb=3663385&return=&ht=&d=&dc=&si=1569558862494_3sp7rkier&cid=&s=1600x1200&rp=
Requested by
Host: ml314.com
URL: https://ml314.com/tag.aspx?2782019
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.252.62.73 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-252-62-73.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
a0620f8f49ab196a27e6439abe2df17f55f4e15bb5dd75bb32e1d593b6167936

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:22 GMT
Content-Encoding
gzip
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Vary
Accept-Encoding
p3P
CP="NON DSP COR ADMo PSAo DEVo BUS COM UNI NAV DEM STA"
Cache-Control
private
Connection
keep-alive
Content-Type
application/javascript; charset=utf-8
Content-Length
484
Expires
0
ud.ashx
in.ml314.com/
20 B
698 B
Script
General
Full URL
https://in.ml314.com/ud.ashx?topiclimit=&cb=2782019
Requested by
Host: ml314.com
URL: https://ml314.com/tag.aspx?2782019
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.175.13.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-35-175-13-58.compute-1.amazonaws.com
Software
Microsoft-IIS/8.5 / ASP.NET
Resource Hash
d0e4a6372d6fb5ffe9505dbe9e94aee8f1b9b96ec8e5e20684cce8b4c5a88fa7

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:21 GMT
Content-Encoding
gzip
Server
Microsoft-IIS/8.5
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Vary
Accept-Encoding
Content-Type
application/javascript; charset=utf-8
Cache-Control
public, no-cache="set-cookie"
Connection
keep-alive
Content-Length
138
Expires
Sat, 28 Sep 2019 04:34:22 GMT
csync.ashx
ml314.com/
Redirect Chain
  • https://tags.bluekai.com/site/20486?limit=0&id=5978151501699112544&redir=https://ml314.com/csync.ashx%3Ffp=$_BK_UUID%26person_id=5978151501699112544%26eid=50056
  • https://ml314.com/csync.ashx?fp=278Fwy9999O%2FyRN5&person_id=5978151501699112544&eid=50056
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=278Fwy9999O%2FyRN5&person_id=5978151501699112544&eid=50056
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.252.62.73 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-252-62-73.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Sat, 28 Sep 2019 00:34:22 GMT

Redirect headers

Location
https://ml314.com/csync.ashx?fp=278Fwy9999O%2FyRN5&person_id=5978151501699112544&eid=50056
Date
Fri, 27 Sep 2019 04:34:22 GMT
Connection
keep-alive
Content-Length
0
BK-Server
35bd
P3P
CP="NOI DSP COR CUR ADMo DEVo PSAo PSDo OUR SAMo BUS UNI NAV", policyref="http://tags.bluekai.com/w3c/p3p.xml"
csync.ashx
ml314.com/
Redirect Chain
  • https://idsync.rlcdn.com/395886.gif?partner_uid=5978151501699112544
  • https://idsync.rlcdn.com/1000.gif?memo=CO6UGBIeChoIARCuXxoTNTk3ODE1MTUwMTY5OTExMjU0NBAAGg0IzqK27AUSBQjoBxAAQgBKAA
  • https://ml314.com/csync.ashx?fp=6e67f63b765426c642c90950500af282bfac8db5932c08ae4752ff2b5eab7287f4cb09cee1a4f8eb&person_id=5978151501699112544&eid=50082
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=6e67f63b765426c642c90950500af282bfac8db5932c08ae4752ff2b5eab7287f4cb09cee1a4f8eb&person_id=5978151501699112544&eid=50082
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.252.62.73 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-252-62-73.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Sat, 28 Sep 2019 00:34:22 GMT

Redirect headers

date
Fri, 27 Sep 2019 04:34:22 GMT
via
1.1 google
status
307
p3p
CP="NOI DSP COR NID CURa ADMa DEVa PSAa PSDa OUR BUS COM INT OTC PUR STA"
location
https://ml314.com/csync.ashx?fp=6e67f63b765426c642c90950500af282bfac8db5932c08ae4752ff2b5eab7287f4cb09cee1a4f8eb&person_id=5978151501699112544&eid=50082
cache-control
no-cache, no-store
timing-allow-origin
*
alt-svc
clear
content-length
0
csync.ashx
ml314.com/
Redirect Chain
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151501699112544%26eid=50220
  • https://pixel.mathtag.com/sync/img?redir=https://ml314.com/csync.ashx%3Ffp=[MM_UUID]%26person_id=5978151501699112544%26eid=50220&mm_bnc&mm_bct&UUID=1bc15d8d-89f2-4d00-b9a6-c1aaea5e249a
  • https://ml314.com/csync.ashx?fp=1bc15d8d-89f2-4d00-b9a6-c1aaea5e249a&person_id=5978151501699112544&eid=50220
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=1bc15d8d-89f2-4d00-b9a6-c1aaea5e249a&person_id=5978151501699112544&eid=50220
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.252.62.73 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-252-62-73.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:21 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Sat, 28 Sep 2019 00:34:22 GMT

Redirect headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Server
MT3 1734 ed2a032 master zrh-pixel-x19
P3P
CP="NOI DSP COR NID CURa ADMa DEVa PSAa PSDa OUR BUS COM INT OTC PUR STA"
Location
https://ml314.com/csync.ashx?fp=1bc15d8d-89f2-4d00-b9a6-c1aaea5e249a&person_id=5978151501699112544&eid=50220
Cache-Control
no-cache
Connection
keep-alive
Content-Type
image/gif
Content-Length
0
Expires
Fri, 27 Sep 2019 04:34:21 GMT
csync.ashx
ml314.com/
Redirect Chain
  • https://sync.crwdcntrl.net/map/c=6985/tp=BOMB?https://ml314.com/csync.ashx%3Ffp%3D%24%7Bprofile_id%7D%26eid%3D50146%26person_id%3D5978151501699112544
  • https://sync.crwdcntrl.net/map/ct=y/c=6985/tp=BOMB?https://ml314.com/csync.ashx%3Ffp%3D%24%7Bprofile_id%7D%26eid%3D50146%26person_id%3D5978151501699112544
  • https://ml314.com/csync.ashx?fp=f7dd9557544444e75f3969dd39dba5bc&eid=50146&person_id=5978151501699112544
43 B
312 B
Image
General
Full URL
https://ml314.com/csync.ashx?fp=f7dd9557544444e75f3969dd39dba5bc&eid=50146&person_id=5978151501699112544
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.252.62.73 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-252-62-73.eu-west-1.compute.amazonaws.com
Software
Microsoft-IIS/10.0 / ASP.NET
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:21 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
image/gif
Cache-Control
private
Connection
keep-alive
Content-Length
43
Expires
Sat, 28 Sep 2019 00:34:22 GMT

Redirect headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:22 GMT
P3P
CP=NOI DSP COR NID PSAa PSDa OUR UNI COM NAV
Location
https://ml314.com/csync.ashx?fp=f7dd9557544444e75f3969dd39dba5bc&eid=50146&person_id=5978151501699112544
Cache-Control
no-cache
X-Server
10.45.7.55
Connection
keep-alive
Content-Length
0
Expires
0
match
ps.eyeota.net/
Redirect Chain
  • https://ps.eyeota.net/pixel?pid=r8hrb20&t=gif
  • https://ps.eyeota.net/pixel/bounce/?pid=r8hrb20&t=gif
  • https://ml314.com/utsync.ashx?eid=50052&et=0&fp=2QOmpmvYJ5L28GWDWQDVK7DrQuMM7KAztUtlnnCCZmlM&gdpr=1&gdpr_consent=&return=https%3A%2F%2Fps.eyeota.net%2Fmatch%3Fbid%3Dr8hrb20%26uid%3Dnil
  • https://ml314.com/csync.ashx?fp=2QOmpmvYJ5L28GWDWQDVK7DrQuMM7KAztUtlnnCCZmlM&person_id=5978151501699112544&eid=50052&return=https%3a%2f%2fps.eyeota.net%2fmatch%3fbid%3dr8hrb20%26uid%3dnil
  • https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
70 B
171 B
Image
General
Full URL
https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
18.197.149.199 Frankfurt am Main, Germany, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-18-197-149-199.eu-central-1.compute.amazonaws.com
Software
/
Resource Hash
de9d3fd0eb948bd294477d0eda60a73b85caff1794803530d0463193a113da98

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Content-Length
70
Content-Type
image/gif

Redirect headers

Date
Fri, 27 Sep 2019 04:34:21 GMT
Server
Microsoft-IIS/10.0
X-AspNet-Version
4.0.30319
X-Powered-By
ASP.NET
Content-Type
text/html; charset=utf-8
Location
https://ps.eyeota.net/match?bid=r8hrb20&uid=nil
Cache-Control
private
Connection
keep-alive
Content-Length
168
Expires
Sat, 28 Sep 2019 00:34:22 GMT
d687c1b7707b466c930381252610bbb5
api.lytics.io/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/ Frame 531F
0
0
Document
General
Full URL
https://api.lytics.io/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/d687c1b7707b466c930381252610bbb5?segments=true&mergestate=true&ts=1569558862561
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.227.192.113 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
113.192.227.35.bc.googleusercontent.com
Software
lytics.io afbca1b0bd5468a6f7b9c99405e0c6c063368ebf /
Resource Hash

Request headers

:method
GET
:authority
api.lytics.io
:scheme
https
:path
/api/me/iframe/43bffbce6f25564c8e2145a11836ff9f/_uid/d687c1b7707b466c930381252610bbb5?segments=true&mergestate=true&ts=1569558862561
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
accept-encoding
gzip, deflate, br
cookie
__cfduid=de7a1940e6801deb3f4839ec13637147e1569558862; seerid=d687c1b7707b466c930381252610bbb5
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

status
200
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Authorization, Cookie, *
access-control-allow-methods
GET
access-control-allow-origin
content-encoding
gzip
content-type
text/html
server
lytics.io afbca1b0bd5468a6f7b9c99405e0c6c063368ebf
date
Fri, 27 Sep 2019 04:34:22 GMT
content-length
294
via
1.1 google
alt-svc
clear
Cookie set /
www.medtargetsystem.com/beacon/portal/ Frame 5CFD
0
0
Document
General
Full URL
https://www.medtargetsystem.com/beacon/portal/?_url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F&_sid=f547e0be-0ebd-4871-b467-fcedb6a3378c&_vid=7c974a5a-0603-4536-ab27-3a3c6c561821&_ak=35-212-8F62AC13&_flash=false&_th=1569558862|1569558862|1
Requested by
Host: www.medtargetsystem.com
URL: https://www.medtargetsystem.com/javascript/beacon.js?v2.5.12
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) / PHP/7.0.19-1+deb.sury.org~trusty+2
Resource Hash

Request headers

Host
www.medtargetsystem.com
Connection
keep-alive
Pragma
no-cache
Cache-Control
no-cache
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
Sec-Fetch-Site
cross-site
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Accept-Encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

Cache-Control
no-store, no-cache, must-revalidate
Content-Encoding
gzip
Content-Type
text/html; charset=UTF-8
Date
Fri, 27 Sep 2019 04:34:23 GMT
Expires
Thu, 19 Nov 1981 08:52:00 GMT
P3P
CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"
Pragma
no-cache
Server
Apache/2.4.7 (Ubuntu)
Set-Cookie
DMDSESSID=6fgpkntlivn11qv7tlh4o77jd5; path=/; HttpOnly
Vary
X-Forwarded-Proto,Accept-Encoding
X-Powered-By
PHP/7.0.19-1+deb.sury.org~trusty+2
Content-Length
6989
Connection
keep-alive
collect.gif
www.medtargetsystem.com/analytics/
0
313 B
Image
General
Full URL
https://www.medtargetsystem.com/analytics/collect.gif?e=1&aid=&vid=7c974a5a-0603-4536-ab27-3a3c6c561821&sid=f547e0be-0ebd-4871-b467-fcedb6a3378c&vh=1&vt=1569558862&pt=1569558862&u=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&r=&t=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&p=2317.47&pm=&ab=&ak=35-212-8F62AC13
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) / PHP/7.0.19-1+deb.sury.org~trusty+2
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:22 GMT
Server
Apache/2.4.7 (Ubuntu)
Connection
keep-alive
X-Powered-By
PHP/7.0.19-1+deb.sury.org~trusty+2
Content-Length
0
Vary
X-Forwarded-Proto
Content-Type
text/html; charset=UTF-8
css
fonts.googleapis.com/
1 KB
477 B
Stylesheet
General
Full URL
https://fonts.googleapis.com/css?family=Lato:400,900
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.bundle.js?ver=0.1.1
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:806::200a Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
ESF /
Resource Hash
4bd7ab38b940371c161b19f0cf34bdfdeaac480eda86b13c29591ed01ed67c36
Security Headers
Name Value
Strict-Transport-Security max-age=31536000
X-Frame-Options SAMEORIGIN
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

strict-transport-security
max-age=31536000
content-encoding
br
last-modified
Fri, 27 Sep 2019 04:34:22 GMT
server
ESF
link
<https://fonts.gstatic.com>; rel=preconnect; crossorigin
status
200
date
Fri, 27 Sep 2019 04:34:22 GMT
x-frame-options
SAMEORIGIN
content-type
text/css; charset=utf-8
access-control-allow-origin
*
cache-control
private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:22 GMT
truncated
/
5 KB
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
d9593473fc4d73446eac1a620bb1bbe590fc80d61d8909484dfee64ae522b787

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
13
subapi.haymarketmedia.com/newsletter/
3 KB
4 KB
XHR
General
Full URL
https://subapi.haymarketmedia.com/newsletter/13
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
3.209.234.104 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-209-234-104.compute-1.amazonaws.com
Software
/ Express
Resource Hash
dc33184388cdcf8d8744da89db61d1633ff8219cc2a82f5c16758ff51a6ef531

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
x-powered-by
Express
etag
W/"d3e-V8fKzUWOVMxpQEouMHWsycPY5EQ"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
text/html; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
3390
13
subapi.haymarketmedia.com/newsletter/
3 KB
4 KB
XHR
General
Full URL
https://subapi.haymarketmedia.com/newsletter/13
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
3.209.234.104 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-209-234-104.compute-1.amazonaws.com
Software
/ Express
Resource Hash
dc33184388cdcf8d8744da89db61d1633ff8219cc2a82f5c16758ff51a6ef531

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
x-powered-by
Express
etag
W/"d3e-V8fKzUWOVMxpQEouMHWsycPY5EQ"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
text/html; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
3390
truncated
/
24 KB
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
65f72bc49f7e243cf332df6eb265d987e4c6e997e7aecd813ceace591f805071

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/gif
collect.gif
www.medtargetsystem.com/analytics/
0
313 B
Image
General
Full URL
https://www.medtargetsystem.com/analytics/collect.gif?e=1&aid=&vid=7c974a5a-0603-4536-ab27-3a3c6c561821&sid=f547e0be-0ebd-4871-b467-fcedb6a3378c&vh=2&vt=1569558862&pt=1569558862&u=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&r=&t=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&p=2420.89&pm=&ab=&ak=35-212-8F62AC13
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.3.171.116 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-3-171-116.compute-1.amazonaws.com
Software
Apache/2.4.7 (Ubuntu) / PHP/7.0.19-1+deb.sury.org~trusty+2
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Server
Apache/2.4.7 (Ubuntu)
Connection
keep-alive
X-Powered-By
PHP/7.0.19-1+deb.sury.org~trusty+2
Content-Length
0
Vary
X-Forwarded-Proto
Content-Type
text/html; charset=UTF-8
truncated
/
82 KB
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
ad9d820f1802abd0f80d4e260c43cd6c92d643c926732a00296821182ae3f9c7

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/svg+xml
/
www.facebook.com/tr/ Frame DDFF
0
0
Document
General
Full URL
https://www.facebook.com/tr/
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f11c:8083:face:b00c:0:25de , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
proxygen-bolt /
Resource Hash
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains

Request headers

:method
POST
:authority
www.facebook.com
:scheme
https
:path
/tr/
content-length
12211
pragma
no-cache
cache-control
no-cache
origin
https://www.empr.com
upgrade-insecure-requests
1
content-type
application/x-www-form-urlencoded
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
accept-encoding
gzip, deflate, br
cookie
fr=00rugHBgn8BPB4Eoo..BdjZFO...1.0.BdjZFO.
Origin
https://www.empr.com
Upgrade-Insecure-Requests
1
Content-Type
application/x-www-form-urlencoded
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

status
200
content-type
text/plain
access-control-allow-origin
https://www.empr.com
access-control-allow-credentials
true
strict-transport-security
max-age=31536000; includeSubDomains
content-length
0
server
proxygen-bolt
date
Fri, 27 Sep 2019 04:34:23 GMT
/
www.facebook.com/tr/ Frame 9E83
0
0
Document
General
Full URL
https://www.facebook.com/tr/
Requested by
Host: connect.facebook.net
URL: https://connect.facebook.net/en_US/fbevents.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a03:2880:f11c:8083:face:b00c:0:25de , Ireland, ASN32934 (FACEBOOK - Facebook, Inc., US),
Reverse DNS
Software
proxygen-bolt /
Resource Hash
Security Headers
Name Value
Strict-Transport-Security max-age=31536000; includeSubDomains

Request headers

:method
POST
:authority
www.facebook.com
:scheme
https
:path
/tr/
content-length
3955
pragma
no-cache
cache-control
no-cache
origin
https://www.empr.com
upgrade-insecure-requests
1
content-type
application/x-www-form-urlencoded
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
accept-encoding
gzip, deflate, br
cookie
fr=00rugHBgn8BPB4Eoo..BdjZFO...1.0.BdjZFO.
Origin
https://www.empr.com
Upgrade-Insecure-Requests
1
Content-Type
application/x-www-form-urlencoded
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

status
200
content-type
text/plain
access-control-allow-origin
https://www.empr.com
access-control-allow-credentials
true
strict-transport-security
max-age=31536000; includeSubDomains
content-length
0
server
proxygen-bolt
date
Fri, 27 Sep 2019 04:34:23 GMT
pathfora.min.js
c.lytics.io/static/
98 KB
20 KB
Script
General
Full URL
https://c.lytics.io/static/pathfora.min.js
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
4215e6200c04a4874f3d23c78af23fcd22b5bc3bc916237fd95c108aaae38735

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
51cac3cf2eeb5a06-VIE
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
cf-cache-status
HIT
last-modified
Wed, 03 Jul 2019 23:03:58 GMT
server
cloudflare
age
5698
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Fri, 27 Sep 2019 06:34:23 GMT
43bffbce6f25564c8e2145a11836ff9f
c.lytics.io/c/
35 B
92 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f?_ts=1569558863188&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_e=pv&utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&_sesstart=1&_tz=2&_ul=en-US&_sz=1600x1200&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3cf2eec5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
43bffbce6f25564c8e2145a11836ff9f
c.lytics.io/c/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f?publicationId=13&channel=home&pagetype=post&tags=oncology%2Crespiratory%20and%20thoracic%20cancers&categories=news&pagename=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%203-Year%20Follow-Up%20Data&author=Brian%20Park%2C%20PharmD&section=home%3Anews%3Afirst-line%20pembrolizumab%20effective%20in%20advanced%20nsclc%2C%20according%20to%203-year%20follow-up%20data&email=nguyentt%40sutterhealth.org&user_id=0&cpn=pcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019&login=nguyentt%40sutterhealth.org&userstate=CA&userspecialty=&userprofession=Physician&_ts=1569558863190&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3cf2eed5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
92 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?gtm.start=1569558861768&event=gtm.js&gtm.uniqueEventId=4&_ts=1569558863190&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3cf2eee5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.AdBlocking=&_ts=1569558863191&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3cf2eef5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.NHTFlag=false&_ts=1569558863191&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3cf2ef05a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
101 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.ArticleId=124026%3A0&_ts=1569558863191&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3cf4efd5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.ArticleType=MPR%20Drug%20News&_ts=1569558863191&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d00f505a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
165 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.MetaData=&_ts=1569558863192&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d01f525a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
101 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Type=post&_ts=1569558863192&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d01f535a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.ScrollDepth=&_ts=1569558863192&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d03f605a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.cmeActivityId=&_ts=1569558863193&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d03f635a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.PrintSource=&_ts=1569558863193&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d05f6c5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.SEOScore=&_ts=1569558863193&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d0efae5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Site.Prefix=omn&_ts=1569558863193&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d0ffb25a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
231 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Site.PublicationId=13&_ts=1569558863194&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d0ffb85a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Author=Brian%20Park%2C%20PharmD&_ts=1569558863194&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d11fc55a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Novo.PremiumMonograph=&_ts=1569558863194&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d12fcb5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Novo.Geolocation=&_ts=1569558863194&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d14fd65a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Activity.Name=&_ts=1569558863195&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d1c80a5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.GenericEvents=&_ts=1569558863195&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d1e80e5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?eComm.CurrencyCode=&_ts=1569558863195&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d1e8105a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
104 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?eComm.OrderId=&_ts=1569558863195&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d1f8175a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Drug.CompanyName=&_ts=1569558863196&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d1f81a5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Novo.IsPremiumMonograph=false&_ts=1569558863196&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d228255a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.GatingType=post%3Anone&_ts=1569558863196&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d2b86e5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Company=&_ts=1569558863196&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d2c8795a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Discipline=&_ts=1569558863197&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d2c87a5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Asset=&_ts=1569558863197&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d2e8825a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.PublishDate=2019-09-17&_ts=1569558863197&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d308985a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
116 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.Curation=false&_ts=1569558863197&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d358be5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Article.WordCount=338&_ts=1569558863198&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d398d35a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?MyCME.CreditType=&_ts=1569558863198&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d3a8db5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?MyCME.ActivityResult=&_ts=1569558863198&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d3a8e25a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.NumberofAdCalls=9&_ts=1569558863199&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d3b8ec5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?eComm.ProductsInCart=&_ts=1569558863199&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d3e8f95a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section1=home&_ts=1569558863199&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d439105a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section2=home%3Anews&_ts=1569558863199&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d4792f5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section3=home%3Anews%3Afirst-line%20pembrolizumab%20effective%20in%20advanced%20nsclc%2C%20according%20to%203-year%20follow-up%20data&_ts=1569558863199&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d489335a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Section4=&_ts=1569558863200&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d489345a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Tags=oncology%2Crespiratory%20and%20thoracic%20cancers&_ts=1569558863200&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d4b9425a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?Page.Categories=news&_ts=1569558863200&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d4c9465a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.LoggedIn=false&_ts=1569558863200&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d519615a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Login=&_ts=1569558863201&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d559805a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SocSSN=&_ts=1569558863201&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d569835a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SSO=3&_ts=1569558863201&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d569885a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SubscriberId=0&_ts=1569558863201&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d599965a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Source=&_ts=1569558863202&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d5b9a55a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Profession=Physician&_ts=1569558863202&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d609b85a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Specialty=&_ts=1569558863202&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d649d15a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SubProfession=&_ts=1569558863202&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d649d25a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.SubSpecialty=&_ts=1569558863203&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d649d55a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.JobTitle=&_ts=1569558863203&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d679e15a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.CampaignCodes=pcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019&_ts=1569558863203&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d699f45a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Country=&_ts=1569558863203&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d6ea0c5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.Company=&_ts=1569558863203&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d72a225a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.CompanySize=&_ts=1569558863204&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d72a255a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.IsHaymarket=false&_ts=1569558863204&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d73a285a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
174 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.IsTracked=true&_ts=1569558863204&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d77a375a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
101 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.IsFromAim=false&_ts=1569558863204&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d78a3a5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
93 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?User.NpiNumber=1619909975&_ts=1569558863205&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d7ca4b5a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
default
c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/
35 B
94 B
Image
General
Full URL
https://c.lytics.io/c/43bffbce6f25564c8e2145a11836ff9f/default?gtm.start=1569558862289&event=gtm.js&gtm.uniqueEventId=3&_ts=1569558863205&_nmob=t&_device=desktop&url=www.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&_uid=d687c1b7707b466c930381252610bbb5&_getid=t&_v=2.0.0&_ca=jstag1
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
server
cloudflare
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
status
200
access-control-allow-methods
GET, POST
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
cf-ray
51cac3d80a755a06-VIE
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Cookie, *
content-length
35
expires
0
d687c1b7707b466c930381252610bbb5
api.lytics.io/api/content/recommend/43bffbce6f25564c8e2145a11836ff9f/user/_uid/
180 KB
34 KB
XHR
General
Full URL
https://api.lytics.io/api/content/recommend/43bffbce6f25564c8e2145a11836ff9f/user/_uid/d687c1b7707b466c930381252610bbb5?limit=30&contentsegment=ee9fe9a51cf2f1774e42f33abc9ca99c&shuffle=true
Requested by
Host: 1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/frontend.min.js?ver=1568281912
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
35.227.192.113 Mountain View, United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
113.192.227.35.bc.googleusercontent.com
Software
lytics.io afbca1b0bd5468a6f7b9c99405e0c6c063368ebf /
Resource Hash
57ae3701ffa24f5cb326c701005d9f7c3ed5e798760d1a7cee4f2bb2183fede6

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
content-encoding
gzip
server
lytics.io afbca1b0bd5468a6f7b9c99405e0c6c063368ebf
access-control-allow-headers
Origin, X-Requested-With, Content-Type, Accept, Authorization, Cookie, *
status
200
access-control-allow-methods
GET
content-type
application/json
access-control-allow-origin
https://www.empr.com
alt-svc
clear
via
1.1 google
pathfora.min.css
c.lytics.io/static/
20 KB
3 KB
Stylesheet
General
Full URL
https://c.lytics.io/static/pathfora.min.css
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/static/pathfora.min.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
58aa5964d6f5dc68b2180e943ea63b6031c0ba83e44d9815e724b10f2f615f9f

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
51cac3cf5f005a06-VIE
date
Fri, 27 Sep 2019 04:34:23 GMT
via
1.1 google
cf-cache-status
HIT
last-modified
Wed, 03 Jul 2019 23:03:58 GMT
server
cloudflare
age
6534
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
text/css; charset=utf-8
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Fri, 27 Sep 2019 06:34:23 GMT
config.js
c.lytics.io/api/program/campaign/config/43bffbce6f25564c8e2145a11836ff9f/
54 KB
8 KB
Script
General
Full URL
https://c.lytics.io/api/program/campaign/config/43bffbce6f25564c8e2145a11836ff9f/config.js
Requested by
Host: c.lytics.io
URL: https://c.lytics.io/api/tag/43bffbce6f25564c8e2145a11836ff9f/lio.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2606:4700:20::6819:5365 , United States, ASN13335 (CLOUDFLARENET - Cloudflare, Inc., US),
Reverse DNS
Software
cloudflare /
Resource Hash
4b3c190f1fd1a6c15ba3202a789424a7fbfb9e6b3fc0a96af1e712d456fc9fd4

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

cf-ray
51cac3d81a7b5a06-VIE
date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 google
cf-cache-status
HIT
server
cloudflare
age
33
expect-ct
max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
vary
Accept-Encoding
content-type
application/javascript
status
200
cache-control
public, max-age=7200
content-encoding
br
expires
Fri, 27 Sep 2019 06:34:24 GMT
registration-profession
subapi.haymarketmedia.com/
589 B
876 B
XHR
General
Full URL
https://subapi.haymarketmedia.com/registration-profession?countryCode=US
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
3.209.234.104 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-209-234-104.compute-1.amazonaws.com
Software
/ Express
Resource Hash
808e5dda9ebf9cae0ae42a7f53c8c335e6f2951724c8a58c15658d0fdd49b61f

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
x-powered-by
Express
etag
W/"24d-pNT5lZLPsLHhX4AYX72K6qXLTk4"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
application/json; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
589
registration-specialty
subapi.haymarketmedia.com/
2 KB
2 KB
XHR
General
Full URL
https://subapi.haymarketmedia.com/registration-specialty?countryCode=US
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-reg-js/develop/production/hmi-registration-ui.vendor.js?ver=0.1.1
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
3.209.234.104 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-3-209-234-104.compute-1.amazonaws.com
Software
/ Express
Resource Hash
2ccc2d6a6ce64b8e30228624183547c2456f8d9597ca456d147f47e95f4fe443

Request headers

Accept
application/json, text/plain, */*
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
cors

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
x-powered-by
Express
etag
W/"686-ZUbw46JA9hG3Fv9uXg61Vkj0+q0"
status
200
access-control-allow-methods
GET, POST, OPTIONS
content-type
application/json; charset=utf-8
access-control-allow-origin
*
access-control-allow-credentials
true
access-control-allow-headers
Content-Type, Connection, Keep-Alive, Content-Length
content-length
1670
truncated
/
88 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
65af014c9562d3ef38dbb4638bef464aa19d2c5899e1872b6ec96da9046168e5

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/svg+xml;charset=utf-8
ads
securepubads.g.doubleclick.net/gampad/
4 KB
2 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=4280026952496210&correlator=542228165720331&output=ldjh&callback=googletag.impl.pubads.callbackProxy1&impl=fif&adsid=NT&eid=21062415%2C21062888%2C21063202&vrg=2019091901&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190927&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2FOOP_prestitial&sz=1x1&ists=1&scp=pos%3DOOP_prestitial&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D124026%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DOncology%252CRespiratory_and_Thoracic_Cancers%26atype%3DMPR_Drug_News%26block%3DHMN_Tecfidera_2019%252Cmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252Cmycme_4638_audience%252Conc_town_wall_audience%252Con_town_wall_audience_use_this%252Con_town_wall_audience_use_this_no_gastro%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cnace_conversations_in_onc_ona%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_cll_may_16%252Cemailops060619%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie_enabled=1&bc=31&abxe=1&lmt=1569558863&dt=1569558863377&dlt=1569558861761&idt=555&frm=20&biw=1585&bih=1200&oid=3&adx=0&ady=3850&adk=1518026067&uci=1&ifi=1&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&dssz=78&icsg=38070591160320&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=1585x3850&msz=1585x1&ga_vid=408063271.1569558862&ga_sid=1569558863&ga_hid=652718221&fws=4&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
c0fd693bcaa9fdf01cb388ba77f6da7713c23a36ff8a07a39c21fdc6a1df8065
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
1971
x-xss-protection
0
google-lineitem-id
132788185
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
138287632758
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
pubads_impl_rendering_2019091901.js
securepubads.g.doubleclick.net/gpt/
62 KB
24 KB
Script
General
Full URL
https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
sffe /
Resource Hash
a29b20518a3bb583278ebb330cba43e072795b7009b39f3479819d00f0833064
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
content-encoding
gzip
x-content-type-options
nosniff
last-modified
Thu, 19 Sep 2019 13:07:51 GMT
server
sffe
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, immutable, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
24151
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:23 GMT
container.html
tpc.googlesyndication.com/safeframe/1-0-35/html/
0
0
Other
General
Full URL
https://tpc.googlesyndication.com/safeframe/1-0-35/html/container.html
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81f::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
/
Resource Hash

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

universal-tag.js
ads.spotible.com/tag/ Frame F961
4 KB
2 KB
Script
General
Full URL
https://ads.spotible.com/tag/universal-tag.js
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
8a846df9c01f4d8d8b6e82c6e505069104280430b3b05d94a13a5b99d7c854aa

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Content-Encoding
gzip
ETag
"5c736e518f66ceaaee6badc00016e1a5"
Vary
Accept-Encoding
Content-Type
application/javascript
Cache-Control
public, max-age=3600
Connection
keep-alive
Content-Length
1767
truncated
/ Frame F961
210 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
f2289c32a34a11c6bce22b234c4930a353703639afcdfe634d866fe6c451c15b

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
osd.js
www.googletagservices.com/activeview/js/current/
77 KB
29 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd.js?cb=%2Fr20100101
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
218087ed3854e672a6627b47c86b3a97e1dad722daa9f509fe522b33b01302a2
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:23 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1569237451959804"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
29169
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:23 GMT
livergraphicdiagnosticsss5_1207852.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
135 KB
135 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/livergraphicdiagnosticsss5_1207852.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
b3647092d3dbff1fcb9fa2a29831d7187aaa105135e08e49946b2c30f8d29a89
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 23:41:59 GMT
server
nginx
etag
"93741d95033d0f1de5fe4b00493dcfab"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
138240
expires
Sun, 27 Oct 2019 04:34:23 GMT
bladdercancerillustrationss_1169393.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
226 KB
226 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/bladdercancerillustrationss_1169393.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
45785b4e3ad45993dfe2737dae902dacfd63b22a9d9421fd53746962d970e984
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:33:47 GMT
server
nginx
etag
"77c60f3b03831e6ac2767c5047f74893"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
231363
expires
Sun, 27 Oct 2019 04:34:23 GMT
fdahq_1495688.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
44 KB
44 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/fdahq_1495688.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
3622b951ea76b210435cfe0389822bfbeb3c690133e6c6fd4724c335b594420a
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:46:08 GMT
server
nginx
etag
"281477ab9f7eb60e6b7d1f61e45fe582"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
45105
expires
Sun, 27 Oct 2019 04:34:23 GMT
hepatitisbss531853195_1353359.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
28 KB
28 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/hepatitisbss531853195_1353359.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
65f2cba11d7a8fb4e042413fdcc6fee12e8723c6ae51bf120b49d7a429178a2e
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 23:54:35 GMT
server
nginx
etag
"cdc768ed36bc7cd647d98f86f71da777"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
28834
expires
Sun, 27 Oct 2019 04:34:23 GMT
thyroid-eye-disease-G-128560636.jpg
www.empr.com/wp-content/uploads/sites/7/2019/09/
361 KB
361 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/09/thyroid-eye-disease-G-128560636.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
df0afa0fef46809ed1dd0f0763d5c8c4ddd678b1363afc17bb32196ed104439d
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Sat, 21 Sep 2019 07:11:26 GMT
server
nginx
etag
"5f674eef32e6ed140c9babdb572989b6"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
369330
expires
Sun, 27 Oct 2019 04:34:23 GMT
genericro_969021.png
www.empr.com/wp-content/uploads/sites/7/2018/12/
177 KB
178 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/genericro_969021.png
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
8accf582ee904ff97dd0439d424181b266e8e55b781563fcd67ba5c1d29fc784
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 23:38:12 GMT
server
nginx
etag
"2ed7f587711d0990fd099dfae036d29c"
x-frame-options
SAMEORIGIN
content-type
image/png
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
181314
expires
Sun, 27 Oct 2019 04:34:23 GMT
multiplesclerosistextns_955299.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
188 KB
189 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/multiplesclerosistextns_955299.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
ccacd4cae5bc75ffc8ea3b271e2286e74aa9a4b3e606321d5ec33fe7811a4a92
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 23:59:16 GMT
server
nginx
etag
"5c5ec802840e0e6c6a514528dc591c44"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
192612
expires
Sun, 27 Oct 2019 04:34:23 GMT
480928ovariancancerns_961282.png
www.empr.com/wp-content/uploads/sites/7/2018/12/
201 KB
201 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/480928ovariancancerns_961282.png
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
f87e8878af3eeb946f4b5fb73c2be7d58a812ce32d90c6b6c88589e506d36556
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Thu, 21 Mar 2019 01:51:21 GMT
server
nginx
etag
"8d9b9a9d83cee26182df16a2a3a53a94"
x-frame-options
SAMEORIGIN
content-type
image/png
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
205437
expires
Sun, 27 Oct 2019 04:34:23 GMT
smokestack_supercell_G_CustomImage.jpg
www.thecardiologyadvisor.com/wp-content/uploads/sites/17/2019/07/
487 KB
488 KB
Image
General
Full URL
https://www.thecardiologyadvisor.com/wp-content/uploads/sites/17/2019/07/smokestack_supercell_G_CustomImage.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
67e1b54a3e28dbeaf8c1a4c70aa952f9b67e38c36c999bcd9e148c90312d474a
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Tue, 30 Jul 2019 07:12:38 GMT
server
nginx
etag
"6a0a5116dad32e7c64124cfec2b97e94"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
498891
expires
Sun, 27 Oct 2019 04:34:23 GMT
xyostedantares_1491322.jpg
media.empr.com/images/2018/10/03/
22 KB
23 KB
Image
General
Full URL
https://media.empr.com/images/2018/10/03/xyostedantares_1491322.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.23 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-23.fra53.r.cloudfront.net
Software
Microsoft-IIS/8.5 /
Resource Hash
81ea12ea0d11e76d3b71e76ce61accc7767b54fa6b7ccfbb33093dc21ac5b236

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Wed, 25 Sep 2019 21:32:44 GMT
via
1.1 8b5bc0831e6dab612582614c3009efa7.cloudfront.net (CloudFront)
age
111513
x-cache
Hit from cloudfront
status
200
content-length
22874
last-modified
Wed, 03 Oct 2018 13:38:50 GMT
server
Microsoft-IIS/8.5
etag
"453d416b1e5bd41:0"
content-type
image/jpeg
access-control-allow-origin
*
cache-control
max-age=31536000
imagefrom
New-Image
x-amz-cf-pop
FRA53-C1
accept-ranges
bytes
x-amz-cf-id
5Cw6lc_8a2ki5XNLAc5V36a8_l78xDOuuFElxtsUSKmBhWdNMS7pfg==
a58b0e37cbad321631b80bb5fdfe6522_clientImage_xlarge_original_1.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
32 KB
33 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/a58b0e37cbad321631b80bb5fdfe6522_clientImage_xlarge_original_1.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
ef4b924da9d8dd8119518323f50bcb8f0a3953228b9995ea6398e4e56209aefe
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 19:42:18 GMT
server
nginx
etag
"de2f1f3c9fd0f5520fe8e57a136ace0f"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
33127
expires
Sun, 27 Oct 2019 04:34:23 GMT
doctorconsultingpatientss1_1300882.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
19 KB
19 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/doctorconsultingpatientss1_1300882.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
736e5b6250ddb3809caee6eee76f4021512fec845668084a453340e4c55377ca
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:48:44 GMT
server
nginx
etag
"baaf6f13f6aab3bc8eada48b5f903199"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
19522
expires
Sun, 27 Oct 2019 04:34:23 GMT
482104manhandsgoutarthriti_964178.jpg
www.rheumatologyadvisor.com/wp-content/uploads/sites/18/2019/07/
66 KB
66 KB
Image
General
Full URL
https://www.rheumatologyadvisor.com/wp-content/uploads/sites/18/2019/07/482104manhandsgoutarthriti_964178.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
6335784e52cf3e719e52018f534484f5c50fd02f59e1a5ad1f6a10a54659573e
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Mon, 22 Jul 2019 07:10:40 GMT
server
nginx
etag
"f0f0da63a5dd40b9ffee19868b5e62c8"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
67355
expires
Sun, 27 Oct 2019 04:34:23 GMT
tourettesyndromess547721980_1314936.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
28 KB
28 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/tourettesyndromess547721980_1314936.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
cb391edd0de3ef3afb6e8960e8609017ccd3f39fd009219154d79dd9bae6b7cb
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Thu, 21 Mar 2019 01:42:12 GMT
server
nginx
etag
"d69aa343cd6d5b97b01a18591d7c31a7"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
28203
expires
Sun, 27 Oct 2019 04:34:23 GMT
passwordg973902638_1523532.jpg
www.empr.com/wp-content/uploads/sites/7/2019/01/
24 KB
25 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/01/passwordg973902638_1523532.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
2d407ec30530520d2ba4a86a5bf4c00d8060ceb0fea21b796ab71b12e1016fd8
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 09:09:32 GMT
server
nginx
etag
"f8aa6327e76cf710ec74960caf2480e1"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
24960
expires
Sun, 27 Oct 2019 04:34:23 GMT
ankylosingspondylitisg87379_1497821.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
14 KB
14 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/ankylosingspondylitisg87379_1497821.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
f431ee593d1222adae2d17c930ea1832d2e6ced7b15ea0fefef2a3314b99210d
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:41:19 GMT
server
nginx
etag
"4584396b5a5d374d06199325cc90d319"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
13993
expires
Sun, 27 Oct 2019 04:34:23 GMT
painmanagementipad_1123350.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
222 KB
223 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/painmanagementipad_1123350.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
6003829935cc8575fbf4e925dace1c877be37ef8a64db4e4d36ba9cccb81ced8
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:52:16 GMT
server
nginx
etag
"e10544aaa8142aad98c8f792023e6f75"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
227393
expires
Sun, 27 Oct 2019 04:34:23 GMT
fycompans_996559.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
37 KB
37 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/fycompans_996559.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
be387391f8d8aafa6d941d5fa812f966e65e5367ec2f41d41b3117f574d8788f
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 22:08:57 GMT
server
nginx
etag
"2e3ead15823141863d867223d5c6c271"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
37539
expires
Sun, 27 Oct 2019 04:34:23 GMT
lungxray_1099089.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
144 KB
145 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/lungxray_1099089.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
b9667f944be3b6b720f6d44491ea4aac51240015386a00969634dccfc800ea79
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Thu, 21 Mar 2019 00:09:10 GMT
server
nginx
etag
"50591903476116ec4c593a5b8f21a333"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
147803
expires
Sun, 27 Oct 2019 04:34:23 GMT
CBD-G-1145537752.jpg
www.empr.com/wp-content/uploads/sites/7/2019/05/
29 KB
29 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/05/CBD-G-1145537752.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
5ce88151c30b9d0b23d2f490871ae8bec44b47bb11277e8a5b8f97a7cdbcebc7
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Sun, 19 May 2019 07:11:27 GMT
server
nginx
etag
"d9d2f05e971d98d4f17b7f32220d3146"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
29889
expires
Sun, 27 Oct 2019 04:34:23 GMT
obesechildstomachg91559816_1228345.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
185 KB
185 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/obesechildstomachg91559816_1228345.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
77fc17c12d4e2de3c7e06431be38590cb48e5883fa8302df83ee9112d9ee8fdf
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Thu, 21 Mar 2019 02:04:17 GMT
server
nginx
etag
"307a7430a7c3e3c247d663efdcb4a7da"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
188930
expires
Sun, 27 Oct 2019 04:34:23 GMT
imfinzi_1215044.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
396 KB
396 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/imfinzi_1215044.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
397486cc51c9de9801c4edd9fb26b4ff81b25b770528ef43cd5ebebb6c541b13
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:40:53 GMT
server
nginx
etag
"bcc532d51fe6cfece965d6933a3fb75f"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
405197
expires
Sun, 27 Oct 2019 04:34:23 GMT
viaskinpeanutpatch_1080585.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
87 KB
87 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/viaskinpeanutpatch_1080585.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
de21751600a5bbe5eede21f33cc022383a3583c34c2d72384fe95fd771e8a8b5
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 19:37:44 GMT
server
nginx
etag
"0b6e576241bc8a39ae49a5dc1557ca99"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
88985
expires
Sun, 27 Oct 2019 04:34:23 GMT
orthonovumrecall_1502239.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
32 KB
32 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/orthonovumrecall_1502239.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
437efc2abdbc224dfc8cc0ba9eb994b46afa5b10bde5d77523bc0c8ab2a87c54
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 19:42:59 GMT
server
nginx
etag
"3cb8189a379ebc7e227808be5ba8d821"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
32818
expires
Sun, 27 Oct 2019 04:34:23 GMT
Gynecomastia-man-boobs-G-187045069.jpg
www.empr.com/wp-content/uploads/sites/7/2019/03/
18 KB
18 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2019/03/Gynecomastia-man-boobs-G-187045069.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
0994e5bf35e818da13d295d3cfa3b04d6682fcf993b897e5d7226425b4e779fd
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Mon, 25 Mar 2019 22:56:32 GMT
server
nginx
etag
"a898473e2ec6547dc7450cb110288174"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
18019
expires
Sun, 27 Oct 2019 04:34:23 GMT
supplementpillsbottlets_991666.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
188 KB
188 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/supplementpillsbottlets_991666.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
1680079026ea2e28d50b62db83178bdbee0839f530ac643f123aa78f19725c28
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Thu, 21 Mar 2019 01:55:51 GMT
server
nginx
etag
"6eb4aef7488248e4a25cf6bda86838c7"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
192499
expires
Sun, 27 Oct 2019 04:34:23 GMT
fdabluero_1143576.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
74 KB
75 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/fdabluero_1143576.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
339cb69fecc1cd06a5fe7f29673ba4430ca24dcbab8a6556999919630fbc355e
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Thu, 21 Mar 2019 01:52:24 GMT
server
nginx
etag
"68987ba85b744131475fce7b9659a8fa"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
76095
expires
Sun, 27 Oct 2019 04:34:23 GMT
fasttrack_1056808.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
124 KB
125 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/fasttrack_1056808.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
3953890072d74373879c64d9a9846f382fe6239fff59aadf94d0152f55018ddf
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 19:56:50 GMT
server
nginx
etag
"ba3b34450aa280434b1e84e7d0a25cff"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
127121
expires
Sun, 27 Oct 2019 04:34:23 GMT
activatedplateletsg17259295_1466249.jpg
www.empr.com/wp-content/uploads/sites/7/2018/12/
22 KB
22 KB
Image
General
Full URL
https://www.empr.com/wp-content/uploads/sites/7/2018/12/activatedplateletsg17259295_1466249.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
52.0.128.45 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-52-0-128-45.compute-1.amazonaws.com
Software
nginx /
Resource Hash
9d7f1238638cb9c3d4092a726046a39f5fbe62ee9b91df6c0e0741c31508302f
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Wed, 20 Mar 2019 21:56:03 GMT
server
nginx
etag
"6ee480cf359331bf7a75c880eff8af86"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
22623
expires
Sun, 27 Oct 2019 04:34:23 GMT
sicklecellanemiass41419244_1341282.jpg
www.hematologyadvisor.com/wp-content/uploads/sites/14/2019/07/
34 KB
35 KB
Image
General
Full URL
https://www.hematologyadvisor.com/wp-content/uploads/sites/14/2019/07/sicklecellanemiass41419244_1341282.jpg
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
34.225.50.222 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-225-50-222.compute-1.amazonaws.com
Software
nginx /
Resource Hash
0d2cacb043d096ef9117abc11a64d3804694a656520f7d312579f751b350052b
Security Headers
Name Value
X-Frame-Options SAMEORIGIN

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

x-amz-server-side-encryption
AES256
date
Fri, 27 Sep 2019 04:34:23 GMT
last-modified
Sat, 10 Aug 2019 07:11:56 GMT
server
nginx
etag
"3283d5cad88da353cddbba27ba87dde7"
x-frame-options
SAMEORIGIN
content-type
image/jpeg
status
200
cache-control
max-age=2592000
accept-ranges
bytes
content-length
35066
expires
Sun, 27 Oct 2019 04:34:23 GMT
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
364 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:9600:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Fri, 27 Sep 2019 04:34:24 GMT
via
1.1 2fe707f3cc1dc569687bcdf81697e284.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
d0b78d8a-4ee1-46c1-8630-158eab10248b
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d8d9150-3379b6b43c5457c0a42c2858;Sampled=0
x-amz-apigw-id
AqOkjGbGIAMFvpg=
content-length
2
x-amz-cf-id
OEkWL7aqB1voJc9eegEKp_VP-Oe0QA9gbQjsFRBFnyt-dhggSfO1sg==
creative-delivery.js
ads.spotible.com/creative/aiv6/
58 KB
20 KB
Script
General
Full URL
https://ads.spotible.com/creative/aiv6/creative-delivery.js
Requested by
Host: ads.spotible.com
URL: https://ads.spotible.com/tag/universal-tag.js
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
8bb87b6a883fd75428afe9c39a568eea8415cb06565b55f77483dcfedf440290

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:23 GMT
Content-Encoding
gzip
ETag
"c009dc01c1c99388f07743f6b22a012f"
Vary
Accept-Encoding
Content-Type
application/javascript
Cache-Control
no-cache
Connection
keep-alive
Content-Length
19906
ads
securepubads.g.doubleclick.net/gampad/
19 KB
6 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=4280026952496210&correlator=542228165720331&output=ldjh&callback=googletag.impl.pubads.callbackProxy2&impl=fif&adsid=NT&eid=21062415%2C21062888%2C21063202%2C21064504&vrg=2019091901&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190927&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2Fleaderboard_top&sz=728x90&scp=pos%3Dleaderboard_top%26amid%3D%26atype%3DMPR_Drug_News%26author%3DSteve%2520Duffy%26block%3DHMN_Tecfidera_2019%2Cmpr_basaglar042616%2CTest%26browser%3DChrome%252074%26cat%3DOncology%2CRespiratory_and_Thoracic_Cancers%26comp%3D%26env%3Dlive%26isnht%3Dfalse%26pagetype%3Dpost%26postID%3D124026%26sid%3DNews%26sponsor%3D%26spr%3D%26ssp%3D%26styleid%3D&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D124026%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DOncology%252CRespiratory_and_Thoracic_Cancers%26atype%3DMPR_Drug_News%26block%3DHMN_Tecfidera_2019%252Cmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252Cmycme_4638_audience%252Conc_town_wall_audience%252Con_town_wall_audience_use_this%252Con_town_wall_audience_use_this_no_gastro%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cnace_conversations_in_onc_ona%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_cll_may_16%252Cemailops060619%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie=ID%3Dea409ddfec7de37e%3AT%3D1569558863%3AS%3DALNI_MaHHdV5SibiVPAFNlrE_xlI8IMDEw&cookie_enabled=1&bc=31&abxe=1&lmt=1569558864&dt=1569558864278&dlt=1569558861761&idt=555&frm=20&biw=1585&bih=1200&oid=3&adx=193&ady=140&adk=2785330797&uci=2&ifi=2&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&dssz=80&icsg=152282361495552&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=1200x-1&msz=1200x-1&psts=Ci8I2d-oP-gB9qLXlIMEggIVsbmAD9G59iGBw_Yh8e3PNLfIz49R0QKLQ6dh4kXH_Q&ga_vid=408063271.1569558862&ga_sid=1569558863&ga_hid=652718221&fws=516&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
4b9832b406d54e1cf6332a305a151a5afc6259d1f58e1f19e3b2da4245796e37
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
5600
x-xss-protection
0
google-lineitem-id
132783265
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
116494044025
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
MPR-lightbox_640x480_Sept_1_.png
cdn1.spotible.com/hashed/65b04db536233c88899551573fc5aa10/
193 KB
194 KB
Image
General
Full URL
https://cdn1.spotible.com/hashed/65b04db536233c88899551573fc5aa10/MPR-lightbox_640x480_Sept_1_.png
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.75 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-75.fra53.r.cloudfront.net
Software
/
Resource Hash
7a1eaf913cf2579fc6b89d3a474cc9def653fa4d36702569d75b54fce2502519

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Wed, 18 Sep 2019 11:41:09 GMT
via
1.1 ab39b007ab81966ada6e7fb1536bf377.cloudfront.net (CloudFront)
age
145134
etag
"65b04db536233c88899551573fc5aa10"
x-cache
Hit from cloudfront
status
200
cache-control
public, max-age=604800
x-amz-cf-pop
FRA53-C1
accept-ranges
bytes
content-length
197880
x-amz-cf-id
dAqYu2y93qXbm-42vB-Cw2w1GvsufeFeJfCLU7JcAM8-WopoUD8apg==
view
securepubads.g.doubleclick.net/pcs/ Frame 000D
0
57 B
Fetch
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsvukIJgpY6I_9m6us_-K8l9mJOz7_fXIaVeDk5IdOeiQS_B8eY0GeBxsbD-eZgj3ZURUqLCl6VlIK5oef-TCXdYYK9_dHE6EWYmQDPaxamfbBWkaPvyhaHcqfvVoSt3NAeM5IGZEiVDGYyUUxUQulv_htoWcM_v2TiijbusREXaAGuUuw0bk6s5gEJYFotPUtQZuTXKGHQSYt7lPtEj6dOXbq3oh_Dr6Z4FxnPWrUzQUEqFS54Xa5jvczC9UnTQRmQXNDyI79FNw7Z5di-wJ27P_Q&sig=Cg0ArKJSzMYxunNUjQVCEAE&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Fri, 27 Sep 2019 04:34:24 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
0
x-xss-protection
0
window_focus.js
tpc.googlesyndication.com/pagead/js/r20190924/r20110914/client/ Frame 000D
2 KB
1 KB
Script
General
Full URL
https://tpc.googlesyndication.com/pagead/js/r20190924/r20110914/client/window_focus.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81f::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
d31b12baad65082a7d404da9971cc9fed871e35f29a5893f815f468f1050491f
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Tue, 24 Sep 2019 13:57:33 GMT
content-encoding
gzip
x-content-type-options
nosniff
age
225411
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
content-disposition
attachment; filename="f.txt"
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
1044
x-xss-protection
0
server
cafe
etag
16885093947315342629
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
public, max-age=1209600
timing-allow-origin
*
expires
Tue, 08 Oct 2019 13:57:33 GMT
osd_listener.js
www.googletagservices.com/activeview/js/current/ Frame 000D
78 KB
29 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd_listener.js?cache=r20110914
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
6182dfae0694d2f06ce0ba9e18b21af30bdc62b4878767761059e6f03cba08e5
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1569237451959804"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
29692
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:24 GMT
init-132dn9au2z77uqg0m5w.js
api.b2c.com/api/ Frame 000D
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-132dn9au2z77uqg0m5w.js?AdUnitID_TopLevel=71146705&AdUnitID=21776212071&AdvertiserID=27496345&OrderID=415436905&LineItemID=132783265&CreativeID=116494044025&CPN=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&sid=News
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:b76e:7a35:805d:7afc Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
1e822defab3de12e4391ba6a49b919dc48024b21f8715d23f1a0f7815e749265

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
5536585125677552591
tpc.googlesyndication.com/simgad/ Frame 000D
68 KB
68 KB
Image
General
Full URL
https://tpc.googlesyndication.com/simgad/5536585125677552591
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81f::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
3a9b25967ee1a016b7bd6cff12850cfa623efc42ea5333d27fa71735eb476969
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 23 Aug 2019 05:31:55 GMT
x-content-type-options
nosniff
age
3020549
x-dns-prefetch-control
off
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
69914
x-xss-protection
0
last-modified
Thu, 02 Feb 2017 14:46:42 GMT
server
sffe
content-type
image/jpeg
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Sat, 22 Aug 2020 05:31:55 GMT
ads
securepubads.g.doubleclick.net/gampad/
19 KB
6 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=4280026952496210&correlator=542228165720331&output=ldjh&callback=googletag.impl.pubads.callbackProxy3&impl=fif&adsid=NT&eid=21062415%2C21062888%2C21063202%2C21064504&vrg=2019091901&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190927&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2Fbox_1&sz=300x250%7C300x600&scp=pos%3Dbox_1%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26atype%3DMPR_Drug_News%26author%3DSteve%2520Duffy%26block%3DHMN_Tecfidera_2019%2Cmpr_basaglar042616%2CTest%26browser%3DChrome%252074%26cat%3DOncology%2CRespiratory_and_Thoracic_Cancers%26comp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26env%3Dlive%26isnht%3Dfalse%26pagetype%3Dpost%26postID%3D124026%26sid%3DNews%26sponsor%3D%26spr%3D448%26ssp%3D%26styleid%3D%26subid%3D0%26usrc%3Dhaymarket%26lid%3D132783265&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D124026%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DOncology%252CRespiratory_and_Thoracic_Cancers%26atype%3DMPR_Drug_News%26block%3DHMN_Tecfidera_2019%252Cmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252Cmycme_4638_audience%252Conc_town_wall_audience%252Con_town_wall_audience_use_this%252Con_town_wall_audience_use_this_no_gastro%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cnace_conversations_in_onc_ona%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_cll_may_16%252Cemailops060619%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie=ID%3Dea409ddfec7de37e%3AT%3D1569558863%3AS%3DALNI_MaHHdV5SibiVPAFNlrE_xlI8IMDEw&cookie_enabled=1&bc=31&abxe=1&lmt=1569558864&dt=1569558864461&dlt=1569558861761&idt=555&frm=20&biw=1585&bih=1200&oid=3&adx=1053&ady=305&adk=204078694&uci=3&ifi=3&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&dssz=79&icsg=152282361495552&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=300x250&msz=300x250&psts=Ci8I2d-oP-gB9qLXlIMEggIVsbmAD9G59iGBw_Yh8e3PNLfIz49R0QKLQ6dh4kXH_Q%2CCi8IobmoP-gB-ZbY_LEDggIVsbmAD9G59iGBw_Yh8e3PNOfA2o9R0QJPLsy37XJLCQ&ga_vid=408063271.1569558862&ga_sid=1569558863&ga_hid=652718221&fws=516&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
62f8d93d806875ae32c11ff4a29c6e8f75b0f84c0767fca9b5f5861462718a32
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
br
x-content-type-options
nosniff
google-mediationgroup-id
-2
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
5588
x-xss-protection
0
google-lineitem-id
132783265
pragma
no-cache
server
cafe
google-mediationtag-id
-2
google-creative-id
138231809751
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
truncated
/ Frame 000D
217 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
6795ad9c1cd6d5ce2951ce1624727b48d0af1a77e5e514786252a36977e364dd

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
view
securepubads.g.doubleclick.net/pcs/ Frame 5AC9
0
57 B
Fetch
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsvXuVm1aFMtr7MpavQRBrKbobmGi6HXrKPDVSKICaXzUBC0s6td129gVT99ikNMiIdX6A6cHELBT4yoSZUv_SDKR-vpytKfzkvt-vTnBC2gM_ysrOYCzxZdfgC5NTfZJPrwdz1hHpQmvJcJOyf95eBs9hOkueldC7QZp6h0G60cKanu-oYkulciAxn34A5MTF8IN38-6SyYK-hQGyyuTCUDfUoMNuV_l50aXefOfbujlCyw2tk-fi-Gsc4LkIBO5Js4gRnDpzXN&sig=Cg0ArKJSzP7aNCin1vhREAE&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Fri, 27 Sep 2019 04:34:24 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
0
x-xss-protection
0
window_focus.js
tpc.googlesyndication.com/pagead/js/r20190924/r20110914/client/ Frame 5AC9
2 KB
1 KB
Script
General
Full URL
https://tpc.googlesyndication.com/pagead/js/r20190924/r20110914/client/window_focus.js
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81f::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
d31b12baad65082a7d404da9971cc9fed871e35f29a5893f815f468f1050491f
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Tue, 24 Sep 2019 13:57:33 GMT
content-encoding
gzip
x-content-type-options
nosniff
age
225411
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
status
200
content-disposition
attachment; filename="f.txt"
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
1044
x-xss-protection
0
server
cafe
etag
16885093947315342629
vary
Accept-Encoding
content-type
text/javascript; charset=UTF-8
cache-control
public, max-age=1209600
timing-allow-origin
*
expires
Tue, 08 Oct 2019 13:57:33 GMT
osd_listener.js
www.googletagservices.com/activeview/js/current/ Frame 5AC9
78 KB
29 KB
Script
General
Full URL
https://www.googletagservices.com/activeview/js/current/osd_listener.js?cache=r20110914
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:825::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
6182dfae0694d2f06ce0ba9e18b21af30bdc62b4878767761059e6f03cba08e5
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
gzip
x-content-type-options
nosniff
server
sffe
etag
"1569237451959804"
vary
Accept-Encoding
content-type
text/javascript
status
200
cache-control
private, max-age=3000
accept-ranges
bytes
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
29692
x-xss-protection
0
expires
Fri, 27 Sep 2019 04:34:24 GMT
init-132dn9au2z77uqg0m5w.js
api.b2c.com/api/ Frame 5AC9
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-132dn9au2z77uqg0m5w.js?AdUnitID_TopLevel=71146705&AdUnitID=21776031401&AdvertiserID=27496345&OrderID=415436905&LineItemID=132783265&CreativeID=138231809751&CPN=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&sid=News
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:b76e:7a35:805d:7afc Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
eb0fc0e3429a9c30bfbc267f31b7285c7427204d40239268f38cfeab42cc0eab

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
12931952424245892654
tpc.googlesyndication.com/simgad/ Frame 5AC9
85 KB
85 KB
Image
General
Full URL
https://tpc.googlesyndication.com/simgad/12931952424245892654
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81f::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
0e4e542509d39b81c72d890c1368211b31dd6de13292643cbcf0e44c67502548
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Sun, 22 Sep 2019 11:35:34 GMT
x-content-type-options
nosniff
age
406730
x-dns-prefetch-control
off
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
86733
x-xss-protection
0
last-modified
Thu, 02 Feb 2017 14:20:42 GMT
server
sffe
content-type
image/jpeg
access-control-allow-origin
*
cache-control
public, max-age=31536000
accept-ranges
bytes
timing-allow-origin
*
expires
Mon, 21 Sep 2020 11:35:34 GMT
ads
securepubads.g.doubleclick.net/gampad/
10 KB
5 KB
XHR
General
Full URL
https://securepubads.g.doubleclick.net/gampad/ads?gdfp_req=1&pvsid=4280026952496210&correlator=542228165720331&output=ldjh&callback=googletag.impl.pubads.callbackProxy4&impl=fif&adsid=NT&eid=21062415%2C21062888%2C21063202%2C21064504&vrg=2019091901&guci=1.2.0.0.2.2.0.0&plat=1%3A32776%2C2%3A16809992%2C8%3A134250504&sc=1&sfv=1-0-35&ecs=20190927&iu=%2F5745%2Fmpr_us%2Fhome%2Fnews%2Fbox_2&sz=300x250&scp=pos%3Dbox_2%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26atype%3DMPR_Drug_News%26author%3DSteve%2520Duffy%26block%3DHMN_Tecfidera_2019%2Cmpr_basaglar042616%2CTest%26browser%3DChrome%252074%26cat%3DOncology%2CRespiratory_and_Thoracic_Cancers%26comp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26env%3Dlive%26isnht%3Dfalse%26pagetype%3Dpost%26postID%3D124026%26sid%3DNews%26sponsor%3D%26spr%3D448%26ssp%3D%26styleid%3D%26subid%3D0%26usrc%3Dhaymarket%26lid%3D132783265&eri=1&cust_params=pagetype%3Dpost%26sponsor%3D%26comp%3D%26author%3DSteve%2520Duffy%26postID%3D124026%26env%3Dlive%26sid%3DNews%26styleid%3D%26cat%3DOncology%252CRespiratory_and_Thoracic_Cancers%26atype%3DMPR_Drug_News%26block%3DHMN_Tecfidera_2019%252Cmpr_basaglar042616%252CTest%26isnht%3Dfalse%26browser%3DChrome%252074%26amid%3D7ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%26spr%3D448%26ssp%3D%26cpn%3Dpcp_md%252Cfp_md%252Cpcp_all%252Charvonitbg%252Cepclusalistb_jan2019%252Cepclusa_april_2019%26subid%3D0%26usrc%3Dhaymarket%26eid%3D4765f0213a10614f6c52b4556676d479ec4f181705feaedbccdcef78c850b74a%26LyticsSegments%3Dga_med_nomycme%252Cga_med_nht_false%252Cmycme_rheum_survey_audience%252Cmycme_4638_audience%252Conc_town_wall_audience%252Con_town_wall_audience_use_this%252Con_town_wall_audience_use_this_no_gastro%252C3_day_visitors_neuro_ca_empr%252Cblackfriday_notunknown%252Cactivity_5126_audience%252Cmycme_endofyearsale_noanonymous_nosdc%252Caudience_for_mlk_sale%252Cnot_unknown_5770%252Cmycme_activity_5762%252Call%252Csmt_new%252Cly_reporting_from_email%252Cly_reporting_has_visited_web%252Cly_reporting_multi_session_visitor%252Cly_reporting_last_visit_within_day%252Cly_reporting_last_visit_within_week%252Cly_reporting_last_visit_within_month%252Cly_reporting_last_visit_within_3_months%252Cly_known_email%252Cly_repeat_visitor%252Cly_international_visitor%252Cly_uses_desktop%252Cly_from_email%252Cknown%252Call_time_visitors%252Cmycme_allergy_all_except_4797_completes%252Cmycme_hiv_all_except_4670_completes%252Cmycme_internal_med_all_except_4670_completes%252Cmycme_allergy_all_except_4744_completes%252Cmycme_psychiatry_all_except_4812_completes%252Cmycme_cardiology_all_except_cardiology_pas%252Cmycme_dermatology_all_except_4831_completes%252Cmycme_pediatrics_all_except_4354_completes%252Cmycme_acc_next_activity_promo_no_4523%252Cmycme_acc_next_activity_promo_no_4524%252Cmycme_acc_next_activity_promo_no_4525%252Cmycme_acc_next_activity_promo_no_4526%252Cmycme_acc_next_activity_promo_no_4593%252Cmycme_acc_next_activity_promo_no_4595%252Cmycme_acc_next_activity_promo_no_4710%252Cmycme_acc_next_activity_promo_no_4804%252Cmycme_acc_next_activity_promo_no_4834%252Cmycme_acc_next_activity_promo_no_4800%252Cmycme_acc_next_activity_promo_no_4792%252Cmycme_acc_next_activity_promo_no_4511%252Cmycme_acc_next_activity_promo_no_4529%252Cmycme_acc_next_activity_promo_no_4558%252Cmycme_acc_next_activity_promo_no_4634%252Cmycme_impact_next_activity_promo_no_4740%252Cmycme_impact_next_activity_promo_no_4757%252Cmycme_impact_next_activity_promo_no_4842%252Cmycme_impact_next_activity_promo_no_4816%252Cmycme_impact_next_activity_promo_no_4897%252Cmycme_impact_next_activity_promo_no_4727%252Cmycme_impact_next_activity_promo_no_4755%252Cmycme_impact_next_activity_promo_no_4791%252Cmycme_impact_next_activity_promo_no_47911%252Cmycme_impact_next_activity_promo_no_4826%252Cmycme_impact_next_activity_promo_no_4815%252Cce_excluding_mpr_print_subscribers%252Cce_excluding_ca_print_subscribers%252Cga_med_known%252Cnace_conversations_in_onc_ona%252Cmycme_homepage_ibs_town_wall_%252Cmycme_ddw_nash%252Cmycme_cll_may_16%252Cemailops060619%252Cmycme_activity_5841_2%252Cmycme_pediatrics_activity_5591&cookie=ID%3Dea409ddfec7de37e%3AT%3D1569558863%3AS%3DALNI_MaHHdV5SibiVPAFNlrE_xlI8IMDEw&cookie_enabled=1&bc=31&abxe=1&lmt=1569558864&dt=1569558864600&dlt=1569558861761&idt=555&frm=20&biw=1585&bih=1200&oid=3&adx=1053&ady=1176&adk=3917873969&uci=4&ifi=4&u_tz=120&u_his=2&u_h=1200&u_w=1600&u_ah=1200&u_aw=1600&u_cd=24&u_sd=1&flash=0&url=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&dssz=79&icsg=152282361495552&mso=67108864&std=0&vis=1&dmc=8&scr_x=0&scr_y=0&psz=300x283&msz=300x250&psts=Ci8IobmoP-gB142I-oIEggIVsbmAD9G59iGBw_Yh8e3PNKm9z49R0QJs6oDD42KpaA%2CCi8I2d-oP-gB9qLXlIMEggIVsbmAD9G59iGBw_Yh8e3PNLfIz49R0QKLQ6dh4kXH_Q%2CCi8IobmoP-gB-ZbY_LEDggIVsbmAD9G59iGBw_Yh8e3PNOfA2o9R0QJPLsy37XJLCQ&ga_vid=408063271.1569558862&ga_sid=1569558863&ga_hid=652718221&fws=516&ohw=1585
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
8093a21e641158323c9fff211dc40f36ce2ba34acc25ccd29250e91f1863d238
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Fri, 27 Sep 2019 04:34:24 GMT
content-encoding
br
x-content-type-options
nosniff
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
status
200
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
5169
x-xss-protection
0
google-lineitem-id
-1
pragma
no-cache
server
cafe
google-creative-id
-1
content-type
text/plain; charset=UTF-8
access-control-allow-origin
https://www.empr.com
cache-control
no-cache, must-revalidate
access-control-allow-credentials
true
timing-allow-origin
*
expires
Fri, 01 Jan 1990 00:00:00 GMT
truncated
/ Frame 5AC9
212 B
0
Image
General
Full URL
data:truncated
Protocol
DATA
Server
-, , ASN (),
Reverse DNS
Software
/
Resource Hash
8e5bd81eca075447860e9afe34b66d70acbac9900104fae5f3b480fdc8ae7628

Request headers

User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Content-Type
image/png
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
364 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:9600:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Fri, 27 Sep 2019 04:34:25 GMT
via
1.1 2fe707f3cc1dc569687bcdf81697e284.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
9722a65a-fd48-4b2a-8cbc-4d7234038c02
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d8d9151-4b7561e4cf6c746c36fe5e18;Sampled=0
x-amz-apigw-id
AqOksE1JIAMFeQw=
content-length
2
x-amz-cf-id
baUoiKsMjz3iFZula3AlHNpNB0MrmXzUTb-LqixwNfV8Q3jznUTnSw==
container.html
tpc.googlesyndication.com/safeframe/1-0-35/html/ Frame DEDF
0
0
Document
General
Full URL
https://tpc.googlesyndication.com/safeframe/1-0-35/html/container.html
Requested by
Host: securepubads.g.doubleclick.net
URL: https://securepubads.g.doubleclick.net/gpt/pubads_impl_rendering_2019091901.js
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:81f::2001 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
sffe /
Resource Hash
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

:method
GET
:authority
tpc.googlesyndication.com
:scheme
https
:path
/safeframe/1-0-35/html/container.html
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
accept-encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

status
200
accept-ranges
bytes
vary
Accept-Encoding
content-encoding
gzip
content-type
text/html
timing-allow-origin
*
content-length
3491
date
Thu, 26 Sep 2019 22:24:32 GMT
expires
Fri, 25 Sep 2020 22:24:32 GMT
last-modified
Fri, 21 Jun 2019 14:35:26 GMT
x-content-type-options
nosniff
server
sffe
x-xss-protection
0
cache-control
public, immutable, max-age=31536000
age
22192
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
365 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:9600:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Fri, 27 Sep 2019 04:34:25 GMT
via
1.1 2fe707f3cc1dc569687bcdf81697e284.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
c55aca06-3590-43c8-b4d8-abc34316fafb
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d8d9151-d2ab7c0409192678ef0d6bbe;Sampled=0
x-amz-apigw-id
AqOkvGhLoAMFaNw=
content-length
2
x-amz-cf-id
BJcfBfROqbQGZJrcXV8UVik0kV-WzZhVJywlbfJVboVBKm9ggyjbUA==
report
ads.spotible.com/creative/aiv6/
43 B
191 B
Image
General
Full URL
https://ads.spotible.com/creative/aiv6/report?,1569558864,516001;UNIQUE_USER_GLOBAL!0,1,0;UNIQUE_USER_DAILY!0,1,0;UNIQUE_USER_HOURLY!0,1,0;IMPRESSION!0,1,0!2,1,0
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:24 GMT
Cache-Control
no-store
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
view
securepubads.g.doubleclick.net/pcs/
0
58 B
Image
General
Full URL
https://securepubads.g.doubleclick.net/pcs/view?xai=AKAOjsvjLg5XshNb3tb_EyvFEZ0dp7PFYLMKfwAIJq77u4dOO2kdk7mRXzSdDtptrmYeWebEcbexSRunnX95V_ipkbcaaQhTBIYpXVNcZytSJkG9rMKuOLIBiwJeEuLYl-p3UFts4qIx0AJ9oYIxbKd2Wk7SYfveZ-5qzIn5bm0hovj_7bpwF1bgOD-vL7iRcNOW7taFgLd7X8iaELF22ODO6gZSfQwgrNWPkUW-IhNFMoH6D5UmgGl0iVtLskAgaM7lOyVH_gunEPuNQcF31cCTIxr1-kvLN9X1RFZ0h_wlGxhpOlX1KGtdrKRGcZRfoA&sai=AMfl-YSBpZ1-wgqfAaRULuhwtbv5JNjfcMTAJvmwB7j9mXOLGcVXlYZ8NhXQauCT85LS6mJeAgdrztg8E9a7D3KGY2rcEOlemAXhY6fB2X4GkA&sig=Cg0ArKJSzDKLj3o4NIlHEAE&urlfix=1&adurl=
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
172.217.16.162 , United States, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
fra15s11-in-f2.1e100.net
Software
cafe /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

timing-allow-origin
*
date
Fri, 27 Sep 2019 04:34:24 GMT
x-content-type-options
nosniff
server
cafe
status
200
p3p
policyref="https://googleads.g.doubleclick.net/pagead/gcn_p3p_.xml", CP="CURa ADMa DEVa TAIo PSAo PSDo OUR IND UNI PUR INT DEM STA PRE COM NAV OTC NOI DSP COR"
access-control-allow-origin
*
cache-control
private
content-type
image/gif
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
0
x-xss-protection
0
ad.gif
api-54-245-184-141.b2c.com/api/ Frame 5AC9
43 B
233 B
Image
General
Full URL
https://api-54-245-184-141.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:23c6:3b85:d7f5:6913 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:25 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
/
adtrackapi.haymarketmedia.com/adverttracking/
2 B
365 B
XHR
General
Full URL
https://adtrackapi.haymarketmedia.com/adverttracking/
Requested by
Host: s3.amazonaws.com
URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:9000:20bb:9600:16:bc48:4dc0:93a1 , United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
/
Resource Hash
44136fa355b3678a1146ad16f7e8649e94fb4fc21fe77e8310c060f61caaff8a

Request headers

Sec-Fetch-Mode
cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-type
application/json

Response headers

date
Fri, 27 Sep 2019 04:34:25 GMT
via
1.1 2fe707f3cc1dc569687bcdf81697e284.cloudfront.net (CloudFront)
x-amz-cf-pop
FRA56
x-amzn-requestid
597f48eb-d1b7-4965-964d-bd7be3a48801
status
200
x-cache
Miss from cloudfront
content-type
application/json
access-control-allow-origin
*
x-amzn-trace-id
Root=1-5d8d9151-6dcc391591c26fead653846e;Sampled=0
x-amz-apigw-id
AqOkxH4loAMFq2Q=
content-length
2
x-amz-cf-id
R9Mlm0QK3gIX4bNn61rdyTbX-G5DzhxE6so-j7JQ5_Isf4KlX-vnFg==
ad.gif
api-34-219-221-191.b2c.com/api/ Frame 000D
43 B
233 B
Image
General
Full URL
https://api-34-219-221-191.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:dbb0:2341:5b61:3e04 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:25 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
4
api-54-245-184-141.b2c.com/api/ Frame 5AC9
Redirect Chain
  • https://api-54-245-184-141.b2c.com/api/x?hIO8Wz07ydJEoMhN$dXJsJDAkaHR0cHM6Ly93d3cuZW1wci5jb20vaG9tZS9uZXdzL2ZpcnN0LWxpbmUtcGVtYnJvbGl6dW1hYi1lZmZlY3RpdmUtaW4tYWR2YW5jZWQtbnNjbGMtYWNjb3JkaW5nLXRvLTM...
  • https://api-54-245-184-141.b2c.com:444/api/4?hIO8Wz07ydJEoMhN
43 B
441 B
XHR
General
Full URL
https://api-54-245-184-141.b2c.com:444/api/4?hIO8Wz07ydJEoMhN
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
54.245.184.141 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-54-245-184-141.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:26 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Access-Control-Allow-Origin
null
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Fri, 27 Sep 2019 04:34:25 GMT
Server
openresty
Location
https://api-54-245-184-141.b2c.com:444/api/4?hIO8Wz07ydJEoMhN
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
4
api-34-219-221-191.b2c.com/api/ Frame 000D
Redirect Chain
  • https://api-34-219-221-191.b2c.com/api/x?SjFZ9AIdsawFR0hY$dXJsJDAkaHR0cHM6Ly93d3cuZW1wci5jb20vaG9tZS9uZXdzL2ZpcnN0LWxpbmUtcGVtYnJvbGl6dW1hYi1lZmZlY3RpdmUtaW4tYWR2YW5jZWQtbnNjbGMtYWNjb3JkaW5nLXRvLTM...
  • https://api-34-219-221-191.b2c.com:444/api/4?SjFZ9AIdsawFR0hY
43 B
441 B
XHR
General
Full URL
https://api-34-219-221-191.b2c.com:444/api/4?SjFZ9AIdsawFR0hY
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.219.221.191 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-219-221-191.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:26 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Access-Control-Allow-Origin
null
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Fri, 27 Sep 2019 04:34:25 GMT
Server
openresty
Location
https://api-34-219-221-191.b2c.com:444/api/4?SjFZ9AIdsawFR0hY
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
activeview
pagead2.googlesyndication.com/pcs/ Frame 000D
42 B
110 B
Image
General
Full URL
https://pagead2.googlesyndication.com/pcs/activeview?xai=AKAOjsv7URJhLDZFYSyZunfAJIJpZV_GcGY1KADycBHoV2MmAavFd36t4jwLRdsCfP5ruZTWk34qJ_rGbih7xxI-_A_5EsZnuWr8yed7GDwTTwM&sig=Cg0ArKJSzNw-lIh4co6dEAE&adk=2785330797&tt=-1&bs=1585%2C1200&mtos=1057,1057,1057,1057,1057&tos=1057,0,0,0,0&p=140,429,230,1157&mcvt=1057&rs=3&ht=0&tfs=1025&tls=2082&mc=1&lte=1&bas=0&bac=0&met=no&avms=nio&niot_obs=973&niot_cbk=988&md=2&lm=2&rst=1569558864456&rpt=28&isd=0&msd=0&ext=mvo%3D-1%26brt%3D199&oseid=3&xdi=0&ps=1585%2C4169&ss=1600%2C1200&pt=-1&bin=1&deb=1-1-4-13-20-16-73-20-0-0-0&tvt=2071&r=v&id=osdim&vs=4&za&uc=11&upc=0&tgt=DIV&cl=1&cec=1&clc=1&cac=1&cd=728x90&itpl=3&v=20190923
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:25 GMT
x-content-type-options
nosniff
server
cafe
timing-allow-origin
*
status
200
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
access-control-allow-origin
*
cache-control
no-cache, must-revalidate
content-type
image/gif
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
42
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
x
api-54-245-184-141.b2c.com/api/ Frame 5AC9
0
382 B
Other
General
Full URL
https://api-54-245-184-141.b2c.com/api/x?hIO8Wz07ydJEoMhN$YWRibG9jayQ1MzckMA
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5800:23c6:3b85:d7f5:6913 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-Type
text/plain;charset=UTF-8

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:25 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
Cookie set rt=ifr
bcp.crwdcntrl.net/5/c=14413/rand=608981664/pv=y/ver=1.4/int=%23OpR%2396858%23Total%20Site%20Traffic%20%3A%20www.empr.com/int=%23OpR%2396859%23www.empr.com%20%3A%20Site%20Section%20%3A%20home/int=%2... Frame 2B7F
0
0
Document
General
Full URL
https://bcp.crwdcntrl.net/5/c=14413/rand=608981664/pv=y/ver=1.4/int=%23OpR%2396858%23Total%20Site%20Traffic%20%3A%20www.empr.com/int=%23OpR%2396859%23www.empr.com%20%3A%20Site%20Section%20%3A%20home/int=%23OpR%2396860%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%20%3A%20news/int=%23OpR%2397492%23www.empr.com%20%3A%20Site%20Section%20%3A%20home%20%3A%20news%20%3A%20first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/med=%23OpR%2397539%23Article%20Tags%20%3A%20Oncology%2CRespiratory%20and%20Thoracic%20Cancers/rb=%7B%22url%22%3A%22https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653%22%7D/rt=ifr
Requested by
Host: tags.crwdcntrl.net
URL: https://tags.crwdcntrl.net/c/14413/cc.js?ver=1.4&ns=_cc14413
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.250.208.218 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-250-208-218.eu-west-1.compute.amazonaws.com
Software
/
Resource Hash

Request headers

Host
bcp.crwdcntrl.net
Connection
keep-alive
Pragma
no-cache
Cache-Control
no-cache
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
Sec-Fetch-Site
cross-site
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Accept-Encoding
gzip, deflate, br
Cookie
_cc_dc=1; _cc_id=f7dd9557544444e75f3969dd39dba5bc; _cc_cc="ACZ4nGNQSDNPSbE0NTU3NQGBVHPTNGNLM8uUFGPLlKRE06RkBiCI7Z3ox4AAAFOoCsk%3D"; _cc_aud="ABR4nGNgYGCI7Z3oxwAHABZ3Aco%3D"
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

Access-Control-Allow-Origin
*
Cache-Control
no-cache
Content-Encoding
gzip
Content-Type
text/html;charset=UTF-8
Date
Fri, 27 Sep 2019 04:34:25 GMT
Expires
0
P3P
CP=NOI DSP COR NID PSAa PSDa OUR UNI COM NAV
Pragma
no-cache
Set-Cookie
_cc_id=f7dd9557544444e75f3969dd39dba5bc;Path=/;Domain=crwdcntrl.net;Expires=Tue, 23-Jun-2020 04:06:00 GMT;SameSite=None _cc_cc="ACZ4nGNQSDNPSbE0NTU3NQGBVHPTNGNLM8uUFGPLlKRE06RkBiCI7Z0Y%2BPf%2F%2F%2F%2F8DDDAfX1miyLj2QKG%2F4yMDKcmI9i90xHsy8%2FvyMLY%2B5cfhbM%2FfraEMS%2BdesQGYx9ePIcFxn4wtYcRxp5%2BQh3GvICkBADbUT6y";Version=1;Path=/;Domain=crwdcntrl.net;Expires=Tue, 23-Jun-2020 04:06:00 GMT;Max-Age=23328000;SameSite=None _cc_aud="ABR4nGNgYGCI7Z0YyAADTAwcV2pBDI7bh4AkAEciBM0%3D";Version=1;Path=/;Domain=crwdcntrl.net;Expires=Tue, 23-Jun-2020 04:06:00 GMT;Max-Age=23328000;SameSite=None
Vary
Accept-Encoding
X-Server
10.45.2.32
Content-Length
695
Connection
keep-alive
cs.js
sb.scorecardresearch.com/c2/21948019/
0
400 B
Script
General
Full URL
https://sb.scorecardresearch.com/c2/21948019/cs.js
Requested by
Host: www.googletagmanager.com
URL: https://www.googletagmanager.com/gtm.js?id=GTM-5XFK9V6
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_256_GCM
Server
2.19.43.224 , Ascension Island, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS
a2-19-43-224.deploy.static.akamaitechnologies.com
Software
/
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:25 GMT
Content-Encoding
gzip
Last-Modified
Fri, 08 Apr 2011 23:11:26 GMT
ETag
"d41d8cd98f00b204e9800998ecf8427e:1349196464"
Vary
Accept-Encoding
Content-Type
application/x-javascript
Cache-Control
private, no-transform, max-age=259200
Connection
keep-alive
Content-Length
20
Expires
Mon, 30 Sep 2019 04:34:25 GMT
init-121b5si20pnxjymcwdz.js
api.b2c.com/api/
12 KB
5 KB
Script
General
Full URL
https://api.b2c.com/api/init-121b5si20pnxjymcwdz.js?isNHT=false
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:b76e:7a35:805d:7afc Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
ce3865553499db5a0192eb5377877bb9e8033e0fdb9ef52ba3998ea63d472203

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:25 GMT
content-encoding
gzip
server
openresty
content-type
text/javascript
status
200
cache-control
no-cache, no-store, must-revalidate
expires
-1
collect
www.google-analytics.com/
35 B
109 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j79&a=652718221&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&ul=en-us&de=UTF-8&dt=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&sd=24-bit&sr=1600x1200&vp=1585x1200&je=0&ec=lytics_refresh&ea=undefined&_u=aGDAAAAjQ~&jid=&gjid=&cid=408063271.1569558862&tid=UA-1290429-2&_gid=2019810217.1569558862&gtm=2wg9i15XFK9V6&cd20=ga_med_nomycme%2Cga_med_nht_false%2Call%2Cga_med_known&cd21=&cd22=&cd23=&cd24=&cd25=&cd26=&cd27=&cd28=&cd29=&cd30=Normal%20(74%20segments%20found)&z=282865776
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:815::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Mon, 26 Aug 2019 08:35:10 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
2750355
status
200
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
up
insight.adsrvr.org/track/ Frame 859E
0
0
Document
General
Full URL
https://insight.adsrvr.org/track/up?adv=wxli9bh&ref=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&upid=7fhq4wn&upv=1.1.0
Requested by
Host: js.adsrvr.org
URL: https://js.adsrvr.org/up_loader.1.1.0.js
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
52.51.120.75 Dublin, Ireland, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-52-51-120-75.eu-west-1.compute.amazonaws.com
Software
/
Resource Hash

Request headers

:method
GET
:authority
insight.adsrvr.org
:scheme
https
:path
/track/up?adv=wxli9bh&ref=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&upid=7fhq4wn&upv=1.1.0
pragma
no-cache
cache-control
no-cache
upgrade-insecure-requests
1
user-agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
sec-fetch-mode
nested-navigate
accept
text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3
sec-fetch-site
cross-site
referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
accept-encoding
gzip, deflate, br
Upgrade-Insecure-Requests
1
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Sec-Fetch-Mode
nested-navigate
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653

Response headers

status
200
date
Fri, 27 Sep 2019 04:34:25 GMT
content-type
text/html
cache-control
private,no-cache, must-revalidate
pragma
no-cache
x-aspnet-version
4.0.30319
p3p
CP="NOI DSP COR CUR ADMo DEVo PSAo PSDo OUR SAMo BUS UNI NAV"
collect
www.google-analytics.com/
35 B
103 B
Image
General
Full URL
https://www.google-analytics.com/collect?v=1&_v=j79&a=652718221&t=event&ni=1&_s=1&dl=https%3A%2F%2Fwww.empr.com%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F%3Futm_source%3Dnewsletter%26utm_medium%3Demail%26utm_campaign%3Dmpr-spotlight-hay-20190927%26cpn%3Dpcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019%26hmSubId%3D%26hmEmail%3D8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1%26NID%3D1619909975%26c_id%3D%26email_hash%3D13fcf80b8097eed186e07db19fd3c2c6%26dl%3D0%26mpweb%3D1323-68826-2303653&ul=en-us&de=UTF-8&dt=First-Line%20Pembrolizumab%20Effective%20in%20Advanced%20NSCLC%2C%20According%20to%20Follow-Up%20Data&sd=24-bit&sr=1600x1200&vp=1585x1200&je=0&ec=Scroll%20Depth&ea=%2Fhome%2Fnews%2Ffirst-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data%2F&el=25%25&ev=25&_u=aGDAAAAjQ~&jid=&gjid=&cid=408063271.1569558862&tid=UA-1290429-2&_gid=2019810217.1569558862&gtm=2wg9i15XFK9V6&z=2102475967
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:815::200e Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
Golfe2 /
Resource Hash
8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015
Security Headers
Name Value
X-Content-Type-Options nosniff

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Mon, 26 Aug 2019 08:35:10 GMT
x-content-type-options
nosniff
last-modified
Sun, 17 May 1998 03:00:00 GMT
server
Golfe2
age
2750355
status
200
content-type
image/gif
access-control-allow-origin
*
cache-control
no-cache, no-store, must-revalidate
alt-svc
quic=":443"; ma=2592000; v="46,43",h3-Q046=":443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
35
expires
Mon, 01 Jan 1990 00:00:00 GMT
activeview
pagead2.googlesyndication.com/pcs/ Frame 5AC9
42 B
110 B
Image
General
Full URL
https://pagead2.googlesyndication.com/pcs/activeview?xai=AKAOjsvs4Sx50OC-PzVpLVmQIiiqWFV2fonzHMetoKAjZ_naicftUCX5LTw9TwXk3M3ereg3lAUkJMHcciD-GorSqzXPOI843czHKUmm7y3mZhw&sig=Cg0ArKJSzCeAfntB-4QZEAE&adk=204078694&tt=-1&bs=1585%2C1200&mtos=1057,1057,1057,1057,1057&tos=1057,0,0,0,0&p=305,1053,905,1353&iza=1&mcvt=1057&rs=3&ht=0&tfs=1229&tls=2286&mc=1&lte=1&bas=0&bac=0&met=no&avms=nio&niot_obs=1112&niot_cbk=1126&md=2&lm=2&rst=1569558864594&rpt=23&isd=0&msd=0&ext=mvo%3D-1%26brt%3D149&oseid=3&xdi=0&ps=1585%2C4169&ss=1600%2C1200&pt=-1&bin=1&deb=1-1-4-15-22-16-83-22-0-0-0&tvt=2274&r=v&id=osdim&vs=4&za&uc=11&upc=1&tgt=DIV&cl=1&cec=1&clc=1&cac=1&cd=300x600&itpl=3&v=20190923
Protocol
H2
Security
TLS 1.3, , AES_128_GCM
Server
2a00:1450:4001:80b::2002 Frankfurt am Main, Germany, ASN15169 (GOOGLE - Google LLC, US),
Reverse DNS
Software
cafe /
Resource Hash
ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
Security Headers
Name Value
X-Content-Type-Options nosniff
X-Xss-Protection 0

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

pragma
no-cache
date
Fri, 27 Sep 2019 04:34:25 GMT
x-content-type-options
nosniff
server
cafe
timing-allow-origin
*
status
200
p3p
policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
access-control-allow-origin
*
cache-control
no-cache, must-revalidate
content-type
image/gif
alt-svc
quic="googleads.g.doubleclick.net:443"; ma=2592000; v="46,43",quic=":443"; ma=2592000; v="46,43",h3-Q046="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q046=":443"; ma=2592000,h3-Q043="googleads.g.doubleclick.net:443"; ma=2592000,h3-Q043=":443"; ma=2592000
content-length
42
x-xss-protection
0
expires
Fri, 01 Jan 1990 00:00:00 GMT
x
api-34-219-221-191.b2c.com/api/ Frame 000D
0
382 B
Other
General
Full URL
https://api-34-219-221-191.b2c.com/api/x?SjFZ9AIdsawFR0hY$YWRibG9jayQ1MzQkMA
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:dbb0:2341:5b61:3e04 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-Type
text/plain;charset=UTF-8

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:25 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
ad.gif
api-34-219-221-191.b2c.com/api/
43 B
233 B
Image
General
Full URL
https://api-34-219-221-191.b2c.com/api/ad.gif
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:dbb0:2341:5b61:3e04 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:26 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Connection
keep-alive
Content-Length
43
Content-Type
image/gif
4
api-34-219-221-191.b2c.com/api/
Redirect Chain
  • https://api-34-219-221-191.b2c.com/api/x?tKqdPazai1XIUSUC$dXJsJDAkaHR0cHM6Ly93d3cuZW1wci5jb20vaG9tZS9uZXdzL2ZpcnN0LWxpbmUtcGVtYnJvbGl6dW1hYi1lZmZlY3RpdmUtaW4tYWR2YW5jZWQtbnNjbGMtYWNjb3JkaW5nLXRvLTM...
  • https://api-34-219-221-191.b2c.com:444/api/4?tKqdPazai1XIUSUC
43 B
441 B
XHR
General
Full URL
https://api-34-219-221-191.b2c.com:444/api/4?tKqdPazai1XIUSUC
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.219.221.191 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
ec2-34-219-221-191.us-west-2.compute.amazonaws.com
Software
openresty /
Resource Hash
cf4724b2f736ed1a0ae6bc28f1ead963d9cd2c1fd87b6ef32e7799fc1c5c8bda

Request headers

Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:26 GMT
Last-Modified
Mon, 28 Sep 1970 06:00:00 GMT
Server
openresty
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
image/gif
Access-Control-Allow-Origin
null
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
43
Expires
-1

Redirect headers

Date
Fri, 27 Sep 2019 04:34:26 GMT
Server
openresty
Location
https://api-34-219-221-191.b2c.com:444/api/4?tKqdPazai1XIUSUC
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/html
Access-Control-Allow-Origin
https://www.empr.com
Access-Control-Allow-Credentials
true
Connection
keep-alive
Content-Length
142
x
api-34-219-221-191.b2c.com/api/
0
382 B
Other
General
Full URL
https://api-34-219-221-191.b2c.com/api/x?tKqdPazai1XIUSUC$YWRibG9jayQzMDkkMA
Requested by
Host: www.empr.com
URL: https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
2600:1f14:e96:5802:dbb0:2341:5b61:3e04 Boardman, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software
openresty /
Resource Hash
e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36
Content-Type
text/plain;charset=UTF-8

Response headers

Pragma
no-cache
Date
Fri, 27 Sep 2019 04:34:26 GMT
Server
openresty
Transfer-Encoding
chunked
Access-Control-Allow-Methods
GET, POST, OPTIONS
Content-Type
text/plain
Access-Control-Allow-Origin
https://www.empr.com
Cache-Control
no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials
true
Connection
keep-alive
Expires
-1
close_button2.png
cdn1.spotible.com/hashed/74483a4bff0849849588dbf32a396fe9/
1 KB
2 KB
Image
General
Full URL
https://cdn1.spotible.com/hashed/74483a4bff0849849588dbf32a396fe9/close_button2.png
Protocol
H2
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
143.204.214.75 Seattle, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
server-143-204-214-75.fra53.r.cloudfront.net
Software
/
Resource Hash
f42e34b205a7c2ac4a0997e0b1eb2627e76ee8ae15ac7a15b05954827e186dd9

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

date
Tue, 17 Sep 2019 08:54:47 GMT
via
1.1 ab39b007ab81966ada6e7fb1536bf377.cloudfront.net (CloudFront)
age
236822
etag
"74483a4bff0849849588dbf32a396fe9"
x-cache
Hit from cloudfront
status
200
cache-control
public, max-age=604800
x-amz-cf-pop
FRA53-C1
accept-ranges
bytes
content-length
1429
x-amz-cf-id
5eTKC9XyiOr0J93vaWcOYAELz9usDRyQ_zl7MHsZbqfvjJhK6ffC6A==
report
ads.spotible.com/creative/aiv6/
43 B
191 B
Image
General
Full URL
https://ads.spotible.com/creative/aiv6/report?,1569558864,516003;IMPRESSION!4,1,0!5,1,0
Protocol
HTTP/1.1
Security
TLS 1.2, ECDHE_RSA, AES_128_GCM
Server
34.197.62.58 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),
Reverse DNS
ec2-34-197-62-58.compute-1.amazonaws.com
Software
/
Resource Hash
b1442e85b03bdcaf66dc58c7abb98745dd2687d86350be9a298a1d9382ac849b

Request headers

Sec-Fetch-Mode
no-cors
Referer
https://www.empr.com/home/news/first-line-pembrolizumab-effective-in-advanced-nsclc-according-to-3-year-follow-up-data/?utm_source=newsletter&utm_medium=email&utm_campaign=mpr-spotlight-hay-20190927&cpn=pcp_md,fp_md,pcp_all,harvonitbg,epclusalistb_jan2019,epclusa_april_2019&hmSubId=&hmEmail=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1&NID=1619909975&c_id=&email_hash=13fcf80b8097eed186e07db19fd3c2c6&dl=0&mpweb=1323-68826-2303653
User-Agent
Mozilla/5.0 (Macintosh; Intel Mac OS X 10_14_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/74.0.3729.169 Safari/537.36

Response headers

Date
Fri, 27 Sep 2019 04:34:28 GMT
Cache-Control
no-store
Connection
keep-alive
Content-Length
43
Content-Type
image/gif

Verdicts & Comments Add Verdict or Comment

200 JavaScript Global Variables

These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.

object| onformdata object| onpointerrawupdate number| pamEnabled object| hmAds object| dataLayer object| $ function| jQuery function| cookie object| _cc14413 object| LOTCC object| Digest function| UtilityMove object| core object| __core-js_shared__ object| global object| System function| asap function| Observable function| setImmediate function| clearImmediate object| regeneratorRuntime boolean| _babelPolyfill object| googletag object| ggeac object| closure_memoize_cache_ object| googleToken object| googleIMState object| google_js_reporting_queue function| processGoogleToken object| google_tag_manager string| GoogleAnalyticsObject function| ga string| adTrackProxyPath string| advertTrackingApiUrl boolean| trackImpressionsViewable object| clickedAd boolean| isOverIFrame object| dfpRequests function| waitFor function| DataLayerExist function| AdSlotsRegistered function| TrackPassbackImpression function| TrackImpression function| TrackImpressionViewable function| AdClick function| checkDuplicateImpression function| callApi function| AmazonWebService function| createAdTrackingMessage function| getAJAXObject function| trackAdvert function| xdTrackAdvert function| getRenderedAd function| EventType function| getPageDetails function| getPageName function| getSection1 function| getPageType function| getDevice function| getValueFromTargets function| getPageTypeId function| getBrowser function| getUser function| getDfpTimestamp function| getCookies function| getTimeStamp function| ProcessMouseOut function| ProcessMouseOver function| processIFrameClick function| getDfpUrlFor function| getDfpUrls function| logAdvertRequested object| dataLayerService function| hmHeaderLoginState object| dfpAdSlots object| mapping object| adSlotsConfig object| allowedSlots string| hmHomeUrl string| hmAccountUrl object| hmRegisteredAds boolean| hmAdsLazyload number| hmAdsActiveRefresh boolean| hmAdsCommentsHouse boolean| hmDmdAimEnabled boolean| hmProclivityEnabled boolean| hmAdsActiveRefreshAll boolean| hmAdsBoxReposition boolean| hmAdsLytics object| adSlots number| adDebug object| hmProclivity string| cpn object| haymarketCustomEvents object| google_tag_data object| gaplugins object| gaGlobal object| gaData string| redirect object| CE2 string| __INDIVIDUAL_ONE_VERSION_ev-store_ENFORCE_SINGLETON undefined| __INDIVIDUAL_ONE_VERSION_ev-store object| _atrk_opts function| fbq function| _fbq function| retry function| isIE10OrLater function| detectPrivateMode object| epas function| maropostInitTracking string| name_funnel function| _132350 string| name_funnel1 function| _13235 object| data object| ids undefined| google_measure_js_timing boolean| google_noFetch number| __google_ad_urls_id object| epasAPI object| hm_localize object| hm_gated object| date function| isStorageSupported function| truncateItem function| storeData function| removeData function| retrieveData function| readStorage function| getExpiration object| TenUp object| liosetup object| jstag object| hmAuthNoncePromise function| disqus_config object| hmRegisterPrompt function| hmSetLyticsData function| atrk boolean| _atrk_fired object| ns_ object| google_optimize object| adblockDetector object| pageVars object| wp function| hmOpenRegisterPrompt function| webpackJsonp function| __jstag_onload undefined| initObj string| ly_cid object| AIM object| _ml object| lio string| set_domain function| domain_name function| deleteMaroClickScriptTag function| maroRecordClick function| anchor_event_add function| maroRecordTime function| maroTrackInit object| _0x1af7 function| _0x2623 function| HMIRegistration object| ssoLogin object| ssoRegister function| ttd_dom_ready function| TTDUniversalPixelApi object| optimizely object| pathfora number| google_unique_id object| google_reactive_ads_global_state function| Goog_AdSense_getAdAdapterInstance function| Goog_AdSense_OsdAdapter object| __google_ad_urls object| ampInaboxIframes object| ampInaboxPendingMessages boolean| google_osd_loaded boolean| google_onload_fired function| Goog_Osd_UnloadAdBlock function| Goog_Osd_UpdateElementToMeasure function| google_osd_amcb object| prontoTags object| ProntoCE object| ProntoDOMEvents object| gtm string| string1 string| string2 string| string3 string| string4 string| string5 string| string6 string| string7 string| string8 string| string9 string| string10 number| lySegmentCounter string| result string| key function| checkForCPNSegments function| logit function| __$PP

47 Cookies

Domain/Path Name / Value
.11teamsports.com/ Name: __cfduid
Value: d81a96f02fb630d63a9df4315062dd17c1569558865
.googlesyndication.com/ Name: vscr_sid
Value: a0585129d4a9443d9bba2f602b79ee9f
www.medtargetsystem.com/ Name: DMDSESSID
Value: t91apd20pob94j7kqmlk6n59e1
www.empr.com/ Name: PathforaTest_d32aacecfe87458780ba0a5b22e84019
Value: 0.4075300137014326
www.empr.com/ Name: PathforaTest_853e3ee5e01881b83ab49fe8c2eae359
Value: 0.37206434622850604
www.11teamsports.com/de-de Name: wgPostView
Value: true
www.empr.com/ Name: PathforaTest_845520b7c2ad6c7b2d753bf3b76b1546
Value: 0.7463713281372479
.empr.com/ Name: __gads
Value: ID=ea409ddfec7de37e:T=1569558863:S=ALNI_MaHHdV5SibiVPAFNlrE_xlI8IMDEw
www.empr.com/ Name: PathforaPageView
Value: 1
www.empr.com/ Name: _sess
Value: f547e0be-0ebd-4871-b467-fcedb6a3378c.7c974a5a-0603-4536-ab27-3a3c6c561821.1569558862.2
www.empr.com/ Name: register-pages
Value: 1
www.empr.com/ Name: dmd-vid
Value: 7c974a5a-0603-4536-ab27-3a3c6c561821
www.empr.com/ Name: dmd-ahk
Value: 8be3b5a83b
.empr.com/ Name: seerid
Value: d687c1b7707b466c930381252610bbb5
ad.doubleclick.net/ Name: kxcongstar_data
Value: user%3Aug3giknbo%3B_user%3A1585110865541%3Bkuid%3AM80TYpCC%3B_kuid%3A1585110865542%3Bvisits%3A1%3B_visits%3A1569621600000
.doubleclick.net/ Name: IDE
Value: AHWqTUmxN8rSu1x7V3r99sOp83zCRFa-yiz1tYMViUyFjfDrJZgbgV48bQSZjx-s
.www.empr.com/ Name: seerid
Value: d687c1b7707b466c930381252610bbb5
www.empr.com/ Name: _ccmaid
Value: 5978151501699112544
.zanox.com/ Name: zptpvc
Value: 5C289195S2612523186113880064T0II5C140180S2612523186113880064T0II45475836C0SV1yq62860858031209145753761034679255yb5yb7T2612523186113880064
.googlesyndication.com/ Name: vscr_reqid
Value: hYJyTfEx
.empr.com/ Name: _maro_campaign_id
Value: BAhpA9oMAQ==--13a721e567250d382d80a7d4545534371e8c2ba4
.googlesyndication.com/ Name: vscr_vid
Value: 3ca39f32ff3a47608b634de659966b8b
www.empr.com/ Name: _ccmsi
Value: 1569558862494_3sp7rkier|1569558862494
www.empr.com/ Name: hmUsrc
Value: haymarket
www.empr.com/ Name: shadowAccount
Value: true
www.empr.com/ Name: PathforaTest_33a33bdd982117e2cd8a1be673315252
Value: 0.8212109146073667
www.empr.com/ Name: globalAct
Value: 0
.empr.com/ Name: _maro_account_id
Value: BAhpAisF--37e0a5dc91bbd179df584d1ded7f2656371a9960
www.empr.com/ Name: dmd-sid
Value: f547e0be-0ebd-4871-b467-fcedb6a3378c
www.empr.com/ Name: hmSsoCheck
Value: true
.www.empr.com/ Name: seerses
Value: e
.zanox.com/ Name: zttpvc
Value: 5C289195S2612523186113880064T0II5C140180S2612523186113880064T0II45475836C0SV1yq62860858031209145753761034679255yb5yb7T2612523186113880064
.empr.com/ Name: seerses
Value: e
www.empr.com/ Name: dmd-f547e0be-0ebd-4871-b467-fcedb6a3378c
Value: e30=
.empr.com/ Name: _ga
Value: GA1.2.408063271.1569558862
www.empr.com/ Name: globalActData
Value: {%22subscriber%22:{%22firstName%22:%22Thao%22%2C%22lastName%22:%22Nguyen%22%2C%22email%22:%22nguyentt@sutterhealth.org%22%2C%22displayName%22:%22Thao%20Nguyen%22%2C%22subscriberId%22:0}%2C%22medicalData%22:{%22npiNumber%22:1619909975%2C%22hashedNpiNumber%22:%227ae510fe18e7431582eb749cfc8567497d75868fa53d079af4ef35f92eebbf33%22%2C%22profession%22:{%22id%22:448%2C%22name%22:%22Physician%22}%2C%22subscriberTopics%22:[]}%2C%22publicationId%22:0%2C%22address%22:{%22city%22:%22SAN%20JOSE%22%2C%22stateCode%22:%22CA%22%2C%22postalCode%22:%2295112%22}%2C%22newsLetters%22:[]%2C%22optInMyCmeEmails%22:false%2C%22optInHmiEmails%22:false%2C%22optInThirdPartyEmails%22:false%2C%22optOutRelevantWorkEmails%22:false%2C%22optInScreenedWorkEmails%22:false%2C%22optOutScreenedWorkEmails%22:false%2C%22sendEmailConfirmation%22:false}
.empr.com/ Name: _gat_UA-1290429-2
Value: 1
www.empr.com/ Name: hmNpiId
Value: 1619909975
.empr.com/ Name: __asc
Value: 56eed28316d70ff9a13e51fc8b3
.empr.com/ Name: _maro_contact_id
Value: BAhpA6UmIw==--7a2ae91d148709d3a8aade4e018a13ff525399d3
.empr.com/ Name: __auc
Value: 56eed28316d70ff9a13e51fc8b3
.empr.com/ Name: _fbp
Value: fb.1.1569558862412.761924113
.empr.com/ Name: _gid
Value: GA1.2.2019810217.1569558862
www.empr.com/ Name: spinfo
Value: spem=8t85OaMnAtdseYl1KsHVWpeVp1w148tbPcMzAuUck5E1
.redintelligence.net/ Name: 8lcfmzhxc8d6_uid
Value: d856195bccc8c3ab
www.empr.com/ Name: PathforaTest_48455487baba85f52d70e65e52b8f2d2
Value: 0.07681956550587499
www.empr.com/ Name: adcpn2
Value: pcp_md%2Cfp_md%2Cpcp_all%2Charvonitbg%2Cepclusalistb_jan2019%2Cepclusa_april_2019

84 Console Messages

Source Level URL
Text
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=1.4.1(Line 2)
Message:
JQMIGRATE: Migrate is installed, version 1.4.1
console-api log URL: https://s3.amazonaws.com/haymarket-adtracking-js/prod/adtracking.js(Line 540)
Message:
interactive
console-api log (Line 2)
Message:
DMD AIM data:{}
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] start beginTest
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] adding bait node to DOM
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] start beginTest
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] adding bait node to DOM
console-api log (Line 8)
Message:
logit -ga_med_nomycme
console-api log (Line 8)
Message:
logit -ga_med_nht_false
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_rheum_survey_audience)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_4638_audience)
console-api log (Line 6)
Message:
checkForCPNSegments(onc_town_wall_audience)
console-api log (Line 6)
Message:
checkForCPNSegments(on_town_wall_audience_use_this)
console-api log (Line 6)
Message:
checkForCPNSegments(on_town_wall_audience_use_this_no_gastro)
console-api log (Line 6)
Message:
checkForCPNSegments(3_day_visitors_neuro_ca_empr)
console-api log (Line 6)
Message:
checkForCPNSegments(blackfriday_notunknown)
console-api log (Line 6)
Message:
checkForCPNSegments(activity_5126_audience)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_endofyearsale_noanonymous_nosdc)
console-api log (Line 6)
Message:
checkForCPNSegments(audience_for_mlk_sale)
console-api log (Line 6)
Message:
checkForCPNSegments(not_unknown_5770)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_activity_5762)
console-api log (Line 8)
Message:
logit -all
console-api log (Line 6)
Message:
checkForCPNSegments(all)
console-api log (Line 6)
Message:
checkForCPNSegments(smt_new)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_from_email)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_has_visited_web)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_multi_session_visitor)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_day)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_week)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_month)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_reporting_last_visit_within_3_months)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_known_email)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_repeat_visitor)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_international_visitor)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_uses_desktop)
console-api log (Line 6)
Message:
checkForCPNSegments(ly_from_email)
console-api log (Line 6)
Message:
checkForCPNSegments(known)
console-api log (Line 6)
Message:
checkForCPNSegments(all_time_visitors)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_allergy_all_except_4797_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_hiv_all_except_4670_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_internal_med_all_except_4670_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_allergy_all_except_4744_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_psychiatry_all_except_4812_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_cardiology_all_except_cardiology_pas)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_dermatology_all_except_4831_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_pediatrics_all_except_4354_completes)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4523)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4524)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4525)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4526)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4593)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4595)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4710)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4804)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4834)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4800)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4792)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4511)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4529)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4558)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_acc_next_activity_promo_no_4634)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4740)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4757)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4842)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4816)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4897)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4727)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4755)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4791)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_47911)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4826)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_impact_next_activity_promo_no_4815)
console-api log (Line 6)
Message:
checkForCPNSegments(ce_excluding_mpr_print_subscribers)
console-api log (Line 6)
Message:
checkForCPNSegments(ce_excluding_ca_print_subscribers)
console-api log (Line 8)
Message:
logit -ga_med_known
console-api log (Line 6)
Message:
checkForCPNSegments(nace_conversations_in_onc_ona)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_homepage_ibs_town_wall_)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_ddw_nash)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_cll_may_16)
console-api log (Line 6)
Message:
checkForCPNSegments(emailops060619)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_activity_5841_2)
console-api log (Line 6)
Message:
checkForCPNSegments(mycme_pediatrics_activity_5591)
console-api log (Line 5)
Message:
OK
console-api log URL: https://1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com/wp-content/themes/haymarket/dist/js/iab.min.js?ver=1567085297(Line 1)
Message:
[ABD] exiting test loop - value: false

Indicators

This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.

1au3b422k9zdqzddw3my51gg-wpengine.netdna-ssl.com
accounts.haymarketmedia.com
ads.spotible.com
adservice.google.com
adservice.google.de
adtrackapi.haymarketmedia.com
api-34-219-221-191.b2c.com
api-54-245-184-141.b2c.com
api.b2c.com
api.lytics.io
bcp.crwdcntrl.net
c.lytics.io
cdn1.spotible.com
certify.alexametrics.com
connect.facebook.net
content.maropost.com
d31qbv1cthcecs.cloudfront.net
fonts.googleapis.com
fonts.gstatic.com
idsync.rlcdn.com
in.ml314.com
insight.adsrvr.org
js.adsrvr.org
link.email.empr.com
media.empr.com
ml314.com
mpct1.maropost.com
mt.sitomobile.com
pagead2.googlesyndication.com
pixel.mathtag.com
pixel.tapad.com
ps.eyeota.net
s3.amazonaws.com
sb.scorecardresearch.com
script.crazyegg.com
securepubads.g.doubleclick.net
sp.sitomobile.com
stats.g.doubleclick.net
subapi.haymarketmedia.com
sync.crwdcntrl.net
tags.bluekai.com
tags.crwdcntrl.net
tpc.googlesyndication.com
www.empr.com
www.facebook.com
www.google-analytics.com
www.google.com
www.google.de
www.googletagmanager.com
www.googletagservices.com
www.hematologyadvisor.com
www.medtargetsystem.com
www.rheumatologyadvisor.com
www.thecardiologyadvisor.com
104.111.241.32
143.204.207.113
143.204.214.23
143.204.214.3
143.204.214.38
143.204.214.75
172.217.16.162
18.197.149.199
2.18.233.201
2.19.43.224
2600:1f14:e96:5800:23c6:3b85:d7f5:6913
2600:1f14:e96:5802:b76e:7a35:805d:7afc
2600:1f14:e96:5802:dbb0:2341:5b61:3e04
2600:9000:20bb:1c00:1b:fadc:b780:93a1
2600:9000:20bb:9600:16:bc48:4dc0:93a1
2606:4700:20::6819:5365
2606:4700::6813:9308
2a00:1450:4001:806::200a
2a00:1450:4001:80b::2002
2a00:1450:4001:80b::2003
2a00:1450:4001:815::200e
2a00:1450:4001:81a::2003
2a00:1450:4001:81a::2008
2a00:1450:4001:81f::2001
2a00:1450:4001:820::2004
2a00:1450:4001:825::2002
2a00:1450:400c:c00::9c
2a03:2880:f01c:8012:face:b00c:0:3
2a03:2880:f11c:8083:face:b00c:0:25de
3.209.234.104
34.192.84.248
34.197.62.58
34.219.221.191
34.225.50.222
34.225.65.223
34.250.208.218
34.252.62.73
35.175.13.58
35.190.72.21
35.227.192.113
35.227.248.159
35.238.92.4
52.0.128.45
52.216.171.93
52.3.171.116
52.51.120.75
54.156.255.160
54.245.184.141
93.184.220.113
94.31.29.64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